Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

Abstract

Therapeutic genome editing has advanced rapidly with the development of diverse programmable nucleases, from zinc-finger nucleases and transcription activator-like effector nucleases to clustered regularly interspaced short palindromic repeats (CRISPR)-based systems such as base and prime editors. Despite these breakthroughs, clinical translation remains constrained by the challenge of achieving safe, efficient, and tissue-specific delivery. Viral vectors, particularly adeno-associated viruses, have enabled durable editing in selected organs but are limited by their restricted cargo capacity, immunogenicity, and complex manufacturing. Nonviral platforms, most notably ionizable lipid nanoparticles, have demonstrated remarkable efficacy for hepatic targets, with clinical trials reporting up to 93% protein knockdown after a single dose. An expanding set of emerging modalities, including virus-mimicking nanosystems, cell-derived extracellular vesicles, cell-penetrating peptides, and intelligent-responsive multifunctional scaffolds, further enriches the delivery toolbox by supporting transient expression and programmable targeting across diverse editors and tissues. Parallel advances in high-throughput barcoded screening and machine learning are accelerating vector optimization, while rational chemical modification of payloads improves in vivo stability and specificity. This review provides a comprehensive overview of current and emerging delivery systems for genome editing, highlighting key innovations, unresolved challenges, and interdisciplinary strategies poised to unlock broader therapeutic potential.

Keywords

delivery systems / genome editing / CRISPR–Cas / AAVs / LNPs / VLPs

References

[1] J. A. Doudna and E. Charpentier, “The New Frontier of Genome Engineering with CRISPR-Cas9,” Science 346, no. 6213 (2014): 1258096.

[2] Z. Chen, G. Devi, A. Arif, P. D. Zamore, E. J. Sontheimer, and J. K. Watts, “Tetrazine-Ligated CRISPR sgRNAs for Efficient Genome Editing,” ACS Chemical Biology 17, no. 5 (2022): 1045–1050.

[3] A. Hoy, Y. Y. Zheng, J. Sheng, and M. Royzen, “Bio-Orthogonal Chemistry Conjugation Strategy Facilitates Investigation of N-Methyladenosine and Thiouridine Guide RNA Modifications on CRISPR Activity,” The CRISPR Journal 5, no. 6 (2022): 787–798.

[4] M. Basila, M. L. Kelley, and S. AvB, “Minimal 2'-O-Methyl Phosphorothioate Linkage Modification Pattern of Synthetic Guide RNAs for Increased Stability and Efficient CRISPR-Cas9 Gene Editing Avoiding Cellular Toxicity,” PLoS One 12, no. 11 (2017): e0188593.

[5] A. V. Anzalone, L. W. Koblan, and D. R. Liu, “Genome Editing with CRISPR–Cas Nucleases, base editors, transposases and prime editors,” Nature Biotechnology 38, no. 7 (2020): 824–844.

[6] J. A. Doudna, “The Promise and Challenge of Therapeutic Genome Editing,” Nature 578, no. 7794 (2020): 229–236.

[7] G. A. Newby, J. S. Yen, K. J. Woodard, et al., “Base Editing of Haematopoietic Stem Cells Rescues Sickle Cell Disease in Mice,” Nature 595, no. 7866 (2021): 295–302.

[8] H. Frangoul, D. Altshuler, M. D. Cappellini, et al., “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-thalassemia,” New England Journal of Medicine 384, no. 3 (2021): 252–260.

[9] J. D. Gillmore, E. Gane, J. Taubel, et al., “CRISPR-Cas9 in Vivo Gene Editing for Transthyretin Amyloidosis,” New England Journal of Medicine 385, no. 6 (2021): 493–502.

[10] D. Wang, F. Zhang, and G. Gao, “CRISPR-Based Therapeutic Genome Editing: Strategies and in Vivo Delivery by AAV Vectors,” Cell 181, no. 1 (2020): 136–150.

[11] C. Li and R. J. Samulski, “Engineering Adeno-associated Virus Vectors for Gene Therapy,” Nature Reviews Genetics 21, no. 4 (2020): 255–272.

[12] A. Akinc, M. A. Maier, M. Manoharan, et al., “The Onpattro Story and the Clinical Translation of Nanomedicines Containing Nucleic Acid-Based Drugs,” Nature Nanotechnology 14, no. 12 (2019): 1084–1087.

[13] X. Hou, T. Zaks, R. Langer, and Y. Dong, “Lipid Nanoparticles for mRNA Delivery,” Nature Reviews Materials 6, no. 12 (2021): 1078–1094.

[14] P. R. Cullis and M. J. Hope, “Lipid Nanoparticle Systems for Enabling Gene Therapies,” Molecular Therapy 25, no. 7 (2017): 1467–1475.

[15] R. G. Lee, A. M. Mazzola, M. C. Braun, et al., “Efficacy and Safety of an Investigational Single-course CRISPR Base-editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models,” Circulation 147, no. 3 (2023): 242–253.

[16] G. Neiman, M. W. Costa, H. Han, et al., “A Microphysiological System for Screening Lipid Nanoparticle− mRNA Complexes Predicts in Vivo Heart Transfection Efficacy,” Nature Biomedical Engineering (2025): 1–13.

[17] C. Wang, Y. Xue, T. Markovic, et al., “Blood–brain-barrier-crossing Lipid Nanoparticles for mRNA Delivery to the central Nervous System,” Nature Materials 24, no. 10 (2025): 1653–1663.

[18] M. Tabebordbar, K. A. Lagerborg, A. Stanton, et al., “Directed Evolution of a family of AAV Capsid Variants Enabling Potent Muscle-directed Gene Delivery across Species,” Cell 184, no. 19 (2021): 4919–4938. e22.

[19] Y. Matsuzaki, A. Konno, R. Mochizuki, et al., “Intravenous Administration of the Adeno-associated Virus-PHP. B Capsid Fails to Upregulate Transduction Efficiency in the Marmoset Brain,” Neuroscience Letters 665 (2018): 182–188.

[20] D. Goertsen, N. C. Flytzanis, N. Goeden, et al., “AAV Capsid Variants with Brain-wide Transgene Expression and Decreased Liver Targeting after Intravenous Delivery in Mouse and Marmoset,” Nature Neuroscience 25, no. 1 (2022): 106–115.

[21] A. Raguram, M. An, P. Z. Chen, and D. R. Liu, “Directed Evolution of Engineered Virus-like Particles with Improved Production and Transduction Efficiencies,” Nature Biotechnology 43, no. 10 (2025): 1635–1647.

[22] A. Asokan, J. C. Conway, J. L. Phillips, et al., “Reengineering a Receptor Footprint of Adeno-associated Virus Enables Selective and Systemic Gene Transfer to Muscle,” Nature Biotechnology 28, no. 1 (2010): 79–82.

[23] S. A. Rosenberg, P. Aebersold, and K. Cornetta, “Gene Transfer into Humans—Immunotherapy of Patients with Advanced Melanoma, Using Tumor-infiltrating Lymphocytes Modified by Retroviral Gene Transduction,” New England Journal of Medicine 323, no. 9 (1990), 570–578.

[24] R. M. Blaese, K. W. Culver, A. D. Miller, et al., “T Lymphocyte-directed Gene Therapy for ADA− SCID: Initial Trial Results after 4 Years,” Science 270, no. 5235 (1995): 475–480.

[25] Y.-G. Kim, J. Cha, and S. Chandrasegaran, “Hybrid Restriction Enzymes: Zinc Finger Fusions to Fok I Cleavage Domain,” Proceedings of the National Academy of Sciences of the United States of America 93, no. 3 (1996): 1156–1160.

[26] J. C. Miller, S. Tan, G. Qiao, et al., “A TALE Nuclease Architecture for Efficient Genome Editing,” Nature Biotechnology 29, no. 2 (2011): 143–148.

[27] T. Cermak, E. L. Doyle, and M. Christian, “Efficient Design and Assembly of Custom TALEN and Other TAL Effector-Based Constructs for DNA Targeting,” Nucleic Acids Research 39, no. 12 (2011): e82.

[28] P. Mali, L. Yang, K. M. Esvelt, et al., “RNA-guided human Genome Engineering via Cas9,” Science 339, no. 6121 (2013): 823–826.

[29] Y. Lu, J. Xue, T. Deng, et al., “Safety and Feasibility of CRISPR-edited T Cells in Patients with Refractory Non-small-cell Lung Cancer,” Nature Medicine 26, no. 5 (2020): 732–740.

[30] A. C. Komor, K. T. Zhao, M. S. Packer, et al., “Improved Base Excision Repair Inhibition and Bacteriophage Mu Gam Protein Yields C: G-to-T: A Base Editors with Higher Efficiency and Product Purity,” Science Advances 3, no. 8 (2017): eaao4774.

[31] N. M. Gaudelli, A. C. Komor, H. A. Rees, et al., “Programmable Base Editing of A• T to G• C in Genomic DNA without DNA Cleavage,” Nature 551, no. 7681 (2017): 464–471.

[32] A. C. Komor, Y. B. Kim, M. S. Packer, J. A. Zuris, and D. R. Liu, “Programmable Editing of a Target Base in Genomic DNA without Double-stranded DNA Cleavage,” Nature 533, no. 7603 (2016): 420–424.

[33] A. V. Anzalone, P. B. Randolph, J. R. Davis, et al., “Search-and-replace Genome Editing without Double-strand Breaks or Donor DNA,” Nature 576, no. 7785 (2019): 149–157.

[34] H. Jang, D. H. Jo, C. S. Cho, et al., “Application of Prime Editing to the Correction of Mutations and Phenotypes in Adult Mice with Liver and Eye Diseases,” Nature Biomedical Engineering 6, no. 2 (2022): 181–194.

[35] K. She, Y. Liu, Q. Zhao, et al., “Dual-AAV Split Prime Editor Corrects the Mutation and Phenotype in Mice with Inherited Retinal Degeneration,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 57.

[36] H. Yin, C.-Q. Song, S. Suresh, et al., “Structure-guided Chemical Modification of Guide RNA Enables Potent Non-viral in Vivo Genome Editing,” Nature Biotechnology 35, no. 12 (2017): 1179–1187.

[37] A. R. Han, H. R. Shin, J. Kweon, et al., “Highly Efficient Genome Editing via CRISPR-Cas9 ribonucleoprotein (RNP) Delivery in Mesenchymal Stem Cells,” BMB Reports 57, no. 1 (2024): 60–65.

[38] A. Seki and S. Rutz, “Optimized RNP Transfection for Highly Efficient CRISPR/Cas9-mediated Gene Knockout in Primary T Cells,” Journal of Experimental Medicine 215, no. 3 (2018): 985–997.

[39] K. Musunuru, A. C. Chadwick, T. Mizoguchi, et al., “In Vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates,” Nature 593, no. 7859 (2021): 429–434.

[40] T. Rothgangl, M. K. Dennis, P. J. Lin, et al., “In Vivo Adenine Base Editing of PCSK9 in Macaques Reduces LDL Cholesterol Levels,” Nature Biotechnology 39, no. 8 (2021): 949–957.

[41] J.-Y. Dong, P.-D. Fan, and R. A. Frizzell, “Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-associated Virus,” Human Gene Therapy 7, no. 17 (1996): 2101–2112.

[42] L. Zhou, J. Su, J. Long, et al., “A Universal Strategy for AAV Delivery of Base Editors to Correct Genetic Point Mutations in Neonatal PKU Mice,” Molecular Therapy Methods & Clinical Development 24 (2022): 230–240.

[43] S. Zhi, Y. Chen, G. Wu, et al., “Dual-AAV Delivering Split Prime Editor System for in Vivo Genome Editing,” Molecular Therapy 30, no. 1 (2022): 283–294.

[44] R. Calcedo, H. Morizono, L. Wang, et al., “Adeno-associated Virus Antibody Profiles in Newborns, Children, and Adolescents,” Clinical and Vaccine Immunology 18, no. 9 (2011): 1586–1588.

[45] A. C. Nathwani, E. G. Tuddenham, S. Rangarajan, et al., “Adenovirus-associated Virus Vector–mediated Gene Transfer in Hemophilia B,” New England Journal of Medicine 365, no. 25 (2011): 2357–2365.

[46] J. M. Crudele and J. S. Chamberlain, “Cas9 immunity Creates Challenges for CRISPR Gene Editing Therapies,” Nature Communications 9, no. 1 (2018): 3497.

[47] C. T. Charlesworth, P. S. Deshpande, D. P. Dever, et al., “Identification of Preexisting Adaptive Immunity to Cas9 Proteins in Humans,” Nature Medicine 25, no. 2 (2019): 249–254.

[48] A. Ghaemi, E. Bagheri, K. Abnous, S. M. Taghdisi, M. Ramezani, and M. Alibolandi, “CRISPR-cas9 Genome Editing Delivery Systems for Targeted Cancer Therapy,” Life Sciences 267 (2021): 118969.

[49] N. Hoshyar, S. Gray, H. Han, and G. Bao, “The Effect of Nanoparticle Size on in Vivo Pharmacokinetics and Cellular Interaction,” Nanomedicine 11, no. 6 (2016): 673–692.

[50] J.-W. Yoo, E. Chambers, and S. Mitragotri, “Factors That Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects,” Current Pharmaceutical Design 16, no. 21 (2010): 2298–2307.

[51] Z. Zhang, J. Conniot, J. Amorim, et al., “Nucleic Acid-Based Therapy for Brain Cancer: Challenges and Strategies,” Journal of Controlled Release 350 (2022): 80–92.

[52] H. Choudhury, M. Pandey, R. Mohgan, et al., “Dendrimer-Based Delivery of Macromolecules for the Treatment of Brain Tumor,” Biomaterials Advances 141 (2022): 213118.

[53] D. Kögel, A. Temme, and A. Aigner, “Recent Advances in Development and Delivery of Non-viral Nucleic Acid Therapeutics for Brain Tumor Therapy,” Pharmacology & Therapeutics 266 (2025): 108762.

[54] D. L. Priwitaningrum, J.-B. G. Blondé, A. Sridhar, et al., “Tumor Stroma-containing 3D Spheroid Arrays: A Tool to Study Nanoparticle Penetration,” Journal of Controlled Release 244 (2016): 257–268.

[55] J. D. Martin, K. Toh, M. R. Martin, et al., “Bone Marrow Vessels Are Hyperpermeable to Macromolecules and Nanoscale Medicine in a Size-dependent Manner,” Journal of Controlled Release 382 (2025): 113669.

[56] R. Allen and T. Yokota, “Endosomal Escape and Nuclear Localization: Critical Barriers for Therapeutic Nucleic Acids,” Molecules 29, no. 24 (2024): 5997.

[57] S. Chatterjee, E. Kon, P. Sharma, and D. Peer, “Endosomal Escape: A Bottleneck for LNP-mediated Therapeutics,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 11 (2024): e2307800120.

[58] M. Durymanov and J. Reineke, “Non-viral Delivery of Nucleic Acids: Insight into Mechanisms of Overcoming Intracellular Barriers,” Frontiers in Pharmacology 9 (2018): 971.

[59] A. R. Chandrasekaran, “Nuclease Resistance of DNA Nanostructures,” Nature Reviews Chemistry 5, no. 4 (2021): 225–239.

[60] A. L. Southwell, N. H. Skotte, C. F. Bennett, and M. R. Hayden, “Antisense Oligonucleotide Therapeutics for Inherited Neurodegenerative Diseases,” Trends in Molecular Medicine 18, no. 11 (2012): 634–643.

[61] D. Hartmann and M. J. Booth, “Accessible Light-controlled Knockdown of Cell-free Protein Synthesis Using Phosphorothioate-caged Antisense Oligonucleotides,” Communications Chemistry 6, no. 1 (2023): 59.

[62] D. Sheehan, B. Lunstad, C. M. Yamada, B. G. Stell, M. H. Caruthers, and D. J. Dellinger, “Biochemical Properties of Phosphonoacetate and Thiophosphonoacetate Oligodeoxyribonucleotides,” Nucleic Acids Research 31, no. 14 (2003): 4109–4118.

[63] A. S. Pavlova, K. I. Yakovleva, A. V. Epanchitseva, et al., “An Influence of Modification with Phosphoryl Guanidine Combined with a 2′-O-Methyl or 2′-fluoro Group on the Small-interfering-RNA Effect,” International Journal of Molecular Sciences 22, no. 18 (2021): 9784.

[64] I. A. Bauer and E. V. Dmitrienko, “Amphiphilic Oligonucleotide Derivatives—Promising Tools for Therapeutics,” Pharmaceutics 16, no. 11 (2024): 1447.

[65] R. C. Steffens and E. Wagner, “Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery,” Pharmaceutical Research 40, no. 1 (2023): 47–76.

[66] S. Mishra, L. Y. Peddada, D. I. Devore, and C. M. Roth, “Poly (alkylene oxide) Copolymers for Nucleic Acid Delivery,” Accounts of Chemical Research 45, no. 7 (2012): 1057–1066.

[67] Z. Zhang, A. E. Berns, S. Willbold, and J. Buitenhuis, “Synthesis of Poly (ethylene glycol)(PEG)-grafted Colloidal Silica Particles with Improved Stability in Aqueous Solvents,” Journal of Colloid and Interface Science 310, no. 2 (2007): 446–455.

[68] J. W. T. Malabanan, K. P. Alcantara, P. Jantaratana, et al., “Enhancing Physicochemical Properties and Biocompatibility of Hollow Porous Iron Oxide Nanoparticles through Polymer-Based Surface Modifications,” ACS Applied Bio Materials 6, no. 12 (2023): 5426–5441.

[69] J. Lu, X. Gao, and S. Wang, Advanced Strategies to Evade the Mononuclear Phagocyte System Clearance of Nanomaterials (Wiley Online Library, 2023), 20220045.

[70] H. Zhou, Z. Fan, and P. Y. Li, “Dense and Dynamic Polyethylene Glycol Shells Cloak Nanoparticles from Uptake by Liver Endothelial Cells for Long Blood Circulation,” ACS Nano 12, no. 10 (2018): 10130–10141.

[71] M. Li, S. Jiang, J. Simon, et al., “Brush Conformation of Polyethylene Glycol Determines the Stealth Effect of Nanocarriers in the Low Protein Adsorption Regime,” Nano Letters 21, no. 4 (2021): 1591–1598.

[72] C. Aslan, N. M. Zolbanin, F. Faraji, and R. Jafari, “Exosomes for CRISPR-Cas9 Delivery: The Cutting Edge in Genome Editing,” Molecular Biotechnology 66, no. 11 (2024): 3092–3116.

[73] X. Zhu, M. Gao, Y. Yang, W. Li, J. Bao, and Y. Li, “The CRISPR/Cas9 system delivered by extracellular vesicles,” Pharmaceutics 15, no. 3 (2023): 984.

[74] M. Hosseini-Kharat, K. E. Bremmell, and C. A. Prestidge, “Why Do Lipid Nanoparticles Target the Liver? Understanding of Biodistribution and Liver-specific Tropism,” Molecular Therapy Methods & Clinical Development 33, no. 1 (2025): 101436.

[75] K. Paunovska, S. Da, A. J. Sanchez, M. P. Lokugamage, et al., “The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure,” Nano Letters 22, no. 24 (2022): 10025–10033.

[76] S. T. LoPresti, M. L. Arral, N. Chaudhary, and K. A. Whitehead, “The Replacement of Helper Lipids with Charged Alternatives in Lipid Nanoparticles Facilitates Targeted mRNA Delivery to the Spleen and Lungs,” Journal of Controlled Release 345 (2022): 819–831.

[77] D. Cahn, A. Stern, M. Buckenmeyer, M. Wolf, and G. A. Duncan, “Extracellular Matrix Limits Nanoparticle Diffusion and Cellular Uptake in a Tissue-specific Manner,” ACS Nano 18, no. 46 (2024): 32045–32055.

[78] X. He, Y. Yang, Y. Han, et al., “Extracellular Matrix Physical Properties Govern the Diffusion of Nanoparticles in Tumor Microenvironment,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 1 (2023): e2209260120.

[79] J. Torres, J. K. Valenzuela Oses, A. M. Rabasco-Álvarez, M. L. González-Rodríguez, and M. C. García, “Innovations in Cancer Therapy: Endogenous Stimuli-responsive Liposomes as Advanced Nanocarriers,” Pharmaceutics 17, no. 2 (2025): 245.

[80] P. Mi, “Stimuli-responsive Nanocarriers for Drug Delivery, Tumor Imaging, Therapy and Theranostics,” Theranostics 10, no. 10 (2020): 4557–4588.

[81] J. van Haasteren, J. Li, O. J. Scheideler, N. Murthy, and D. V. Schaffer, “The Delivery Challenge: Fulfilling the Promise of Therapeutic Genome Editing,” Nature Biotechnology 38, no. 7 (2020): 845–855.

[82] S. Uhrig, O. Coutelle, T. Wiehe, L. Perabo, M. Hallek, and H. Büning, “Successful Target Cell Transduction of Capsid-engineered rAAV Vectors Requires Clathrin-dependent Endocytosis,” Gene Therapy 19, no. 2 (2012): 210–218.

[83] Z.-R. Lu and D. Sun, “Mechanism of pH-sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery: Lu and Sun,” Pharmaceutical Research 42, no. 7 (2025): 1065–1077.

[84] W. H. Meisen, Z. B. Nejad, M. Hardy, et al., “Pooled Screens Identify GPR108 and TM9SF2 as Host Cell Factors Critical for AAV Transduction,” Molecular Therapy Methods & Clinical Development 17 (2020): 601–611.

[85] A. M. Dudek, N. Zabaleta, E. Zinn, et al., “GPR108 is a Highly Conserved AAV Entry Factor,” Molecular Therapy 28, no. 2 (2020): 367–381.

[86] S. Pillay, N. Meyer, A. Puschnik, et al., “An Essential Receptor for Adeno-associated Virus Infection,” Nature 530, no. 7588 (2016): 108–112.

[87] F. Sonntag, S. Bleker, B. Leuchs, R. Fischer, and K. A Jr, “Adeno-associated Virus Type 2 Capsids with Externalized VP1/VP2 Trafficking Domains Are Generated Prior to Passage through the Cytoplasm and Are Maintained Until Uncoating Occurs in the Nucleus,” Journal of Virology 80, no. 22 (2006): 11040–11054.

[88] D. McCarty, H. Fu, P. Monahan, C. Toulson, P. Naik, and R. Samulski, “Adeno-associated Virus Terminal Repeat (TR) Mutant Generates Self-complementary Vectors to Overcome the Rate-limiting Step to Transduction in Vivo,” Gene Therapy 10, no. 26 (2003): 2112–2118.

[89] J. M. Levy, W.-H. Yeh, N. Pendse, et al., “Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice via Adeno-associated Viruses,” Nature Biomedical Engineering 4, no. 1 (2020): 97–110.

[90] T. Bus, A. Traeger, and U. S. Schubert, “The Great Escape: How Cationic Polyplexes Overcome the Endosomal Barrier,” Journal of Materials Chemistry B 6, no. 43 (2018): 6904–6918.

[91] L. M. Vermeulen, S. C. De Smedt, K. Remaut, and K. Braeckmans, “The Proton Sponge Hypothesis: Fable or Fact?,” European Journal of Pharmaceutics and Biopharmaceutics 129 (2018): 184–190.

[92] D. Dean, D. Strong, and W. Zimmer, “Nuclear Entry of Nonviral Vectors,” Gene Therapy 12, no. 11 (2005): 881–890.

[93] A. Lam and D. Dean, “Progress and Prospects: Nuclear Import of Nonviral Vectors,” Gene Therapy 17, no. 4 (2010): 439–447.

[94] S. Kim, D. Kim, S. W. Cho, J. Kim, and J.-S. Kim, “Highly Efficient RNA-guided Genome Editing in human Cells via Delivery of Purified Cas9 Ribonucleoproteins,” Genome Research 24, no. 6 (2014): 1012–1019.

[95] M. A. DeWitt, J. E. Corn, and D. Carroll, “Genome Editing via Delivery of Cas9 ribonucleoprotein,” Methods 121 (2017): 9–15.

[96] M. P. Stewart, A. Sharei, X. Ding, G. Sahay, R. Langer, and K. F. Jensen, “In Vitro and Ex Vivo Strategies for Intracellular Delivery,” Nature 538, no. 7624 (2016): 183–192.

[97] J. Geilenkeuser, N. Armbrust, E. Steinmaßl, et al., “Engineered Nucleocytosolic Vehicles for Loading of Programmable Editors,” Cell 188, no. 10 (2025): 2637–2655. e31.

[98] M. Naeem, M. Z. Hoque, M. Ovais, C. Basheer, and I. Ahmad, “Stimulus-responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing,” International Journal of Molecular Sciences 22, no. 20 (2021): 11300.

[99] Q. Sun, X. Sun, X. Ma, et al., “Integration of Nanoassembly Functions for an Effective Delivery Cascade for Cancer Drugs,” Advanced Materials 26, no. 45 (2014): 7615–7621.

[100] L. Tecedor, Y. H. Chen, D. E. Leib, et al., “An AAV Variant Selected through NHP Screens Robustly Transduces the Brain and Drives Secreted Protein Expression in NHPs and Mice,” Science Translational Medicine 17, no. 798 (2025): eadr2531.

[101] J. D. Finn, T. C. Nichols, N. Svoronos, et al., “The Efficacy and the Risk of Immunogenicity of FIX Padua (R338L) in Hemophilia B Dogs Treated by AAV Muscle Gene Therapy,” Blood, The Journal of the American Society of Hematology 120, no. 23 (2012): 4521–4523.

[102] M. Kumar, B. Keller, N. Makalou, and R. E. Sutton, “Systematic Determination of the Packaging Limit of Lentiviral Vectors,” Human Gene Therapy 12, no. 15 (2001): 1893–1905.

[103] D. Böck, T. Rothgangl, L. Villiger, et al., “In Vivo Prime Editing of a Metabolic Liver Disease in Mice,” Science Translational Medicine 14, no. 636 (2022): eabl9238.

[104] H. Zhang, D. Liu, K. Yang, Z. Liang, and M. Li, “Ionizable Guanidine-Based Lipid Nanoparticle for Targeted mRNA Delivery and Cancer Immunotherapy,” Science Advances 11, no. 43 (2025): eadx5970.

[105] L. Warren, P. D. Manos, T. Ahfeldt, et al., “Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of human Cells with Synthetic Modified mRNA,” Cell Stem Cell 7, no. 5 (2010): 618–630.

[106] K. J. Kauffman, J. R. Dorkin, J. H. Yang, et al., “Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs,” Nano Letters 15, no. 11 (2015): 7300–7306.

[107] R. Hołubowicz, S. W. Du, J. Felgner, et al., “Safer and Efficient Base Editing and Prime Editing via Ribonucleoproteins Delivered through Optimized Lipid-nanoparticle Formulations,” Nature Biomedical Engineering 9, no. 1 (2025): 57–78.

[108] N. Luo, J. Li, Y. Chen, et al., “Hepatic Stellate Cell Reprogramming via Exosome-mediated CRISPR/dCas9-VP64 Delivery,” Drug Delivery 28, no. 1 (2021): 10–18.

[109] S. Ling, X. Zhang, Y. Dai, et al., “Customizable Virus-like Particles Deliver CRISPR–Cas9 ribonucleoprotein for Effective Ocular Neovascular and Huntington's Disease Gene Therapy,” Nature Nanotechnology 20, no. 4 (2025): 543–553.

[110] S. Banskota, A. Raguram, S. Suh, et al., “Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins,” Cell 185, no. 2 (2022): 250–265. e16.

[111] S. L. Ginn, A. K. Amaya, I. E. Alexander, M. Edelstein, and M. R. Abedi, “Gene Therapy Clinical Trials Worldwide to 2017: An Update,” The Journal of Gene Medicine 20, no. 5 (2018): e3015.

[112] M. A. Haque, A. Shrestha, C. M. Mikelis, and G. Mattheolabakis, “Comprehensive Analysis of Lipid Nanoparticle Formulation and Preparation for RNA Delivery,” International Journal of Pharmaceutics: X 8 (2024): 100283.

[113] B. N. Aldosari, I. M. Alfagih, and A. S. Almurshedi, “Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines,” Pharmaceutics 13, no. 2 (2021): 206.

[114] K. Chen, H. Han, S. Zhao, et al., “Lung and Liver Editing by Lipid Nanoparticle Delivery of a Stable CRISPR–Cas9 ribonucleoprotein,” Nature Biotechnology 43, no. 9 (2025): 1445–1457.

[115] J. Zeng, D. E. Bauer, Y. Wu, et al., “Highly Efficient Therapeutic Gene Editing of BCL11A Enhancer in Human Hematopoietic Stem Cells from Ss-Hemoglobinopathy Patients for Fetal Hemoglobin Induction,” Blood 132 (2018): 3482.

[116] E. De Dreuzy, J. Heath, P. Sousa, et al., “Robust Pre-clinical Results and Large-scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD,” Blood 136 (2020): 45–46.

[117] J. R. Davis, X. Wang, I. P. Witte, et al., “Efficient in Vivo Base Editing via Single Adeno-associated Viruses with Size-optimized Genomes Encoding Compact Adenine Base Editors,” Nature Biomedical Engineering 6, no. 11 (2022): 1272–1283.

[118] F. A. Ran, L. Cong, W. X. Yan, et al., “In Vivo Genome Editing Using Staphylococcus aureus Cas9,” Nature 520, no. 7546 (2015): 186–191.

[119] Y. Zhang, H. Li, Y.-L. Min, et al., “Enhanced CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-complementary AAV Delivery System,” Science Advances 6, no. 8 (2020): eaay6812.

[120] Q. Li, J. Su, Y. Liu, et al., “In Vivo PCSK9 Gene Editing Using an All-in-one Self-cleavage AAV-CRISPR System,” Molecular Therapy Methods & Clinical Development 20 (2021): 652–659.

[121] S. G. Morsy, J. M. Tonne, Y. Zhu, et al., “Divergent Susceptibilities to AAV-SaCas9-gRNA Vector-mediated Genome-editing in a Single-cell-derived Cell Population,” BMC Research Notes 10, no. 1 (2017): 720.

[122] L. Villiger, T. Rothgangl, D. Witzigmann, et al., “In Vivo Cytidine Base Editing of Hepatocytes without Detectable off-target Mutations in RNA and DNA,” Nature Biomedical Engineering 5, no. 2 (2021): 179–189.

[123] A. Muller, J. Sullivan, W. Schwarzer, et al., “High-efficiency Base Editing in the Retina in Primates and human Tissues,” Nature Medicine 31, no. 2 (2025): 490–501.

[124] J. R. Davis, S. Banskota, J. M. Levy, et al., “Efficient Prime Editing in Mouse Brain, Liver and Heart with Dual AAVs,” Nature Biotechnology 42, no. 2 (2024): 253–264.

[125] S. Yu, Y. Yao, H. Xiao, et al., “Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to both X4-and R5-tropic human Immunodeficiency Virus Type 1 Infection,” Human Gene Therapy 29, no. 1 (2018): 51–67.

[126] S. V. Patil, B. R. Kaipa, S. Ranshing, et al., “Lentiviral Mediated Delivery of CRISPR/Cas9 Reduces Intraocular Pressure in a Mouse Model of myocilin glaucoma,” Scientific Reports 14, no. 1 (2024): 6958.

[127] A. Lombardo, P. Genovese, C. M. Beausejour, et al., “Gene Editing in human Stem Cells Using Zinc Finger Nucleases and Integrase-defective Lentiviral Vector Delivery,” Nature Biotechnology 25, no. 11 (2007): 1298–1306.

[128] F. Nidhi and S. Tomatsu, “Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA,” International Journal of Molecular Sciences 26, no. 14 (2025): 6616.

[129] S. Ling, S. Yang, X. Hu, et al., “Lentiviral Delivery of co-packaged Cas9 mRNA and a Vegfa-targeting Guide RNA Prevents Wet Age-related Macular Degeneration in Mice,” Nature Biomedical Engineering 5, no. 2 (2021): 144–156.

[130] M. Schiwon, E. Ehrke-Schulz, A. Oswald, et al., “One-vector System for Multiplexed CRISPR/Cas9 against hepatitis B Virus cccDNA Utilizing High-capacity Adenoviral Vectors,” Molecular Therapy Nucleic Acids 12 (2018): 242–253.

[131] J. Gao, T. Bergmann, W. Zhang, M. Schiwon, E. Ehrke-Schulz, and A. Ehrhardt, “Viral Vector-Based Delivery of CRISPR/Cas9 and Donor DNA for Homology-directed Repair in an in Vitro Model for Canine Hemophilia B,” Molecular Therapy Nucleic Acids 14 (2019): 364–376.

[132] M. Brescia, J. M. Janssen, J. Liu, and M. A. Gonçalves, “High-capacity Adenoviral Vectors Permit Robust and Versatile Testing of DMD Gene Repair Tools and Strategies in human Cells,” Cells 9, no. 4 (2020): 869.

[133] F. Tasca, M. Brescia, J. Liu, J. M. Janssen, K. Mamchaoui, and M. A. Gonçalves, “High-capacity Adenovector Delivery of Forced CRISPR-Cas9 Heterodimers Fosters Precise Chromosomal Deletions in human Cells,” Molecular Therapy Nucleic Acids 31 (2023): 746–762.

[134] C. Li, A. S. Mishra, S. Gil, et al., “Targeted Integration and High-level Transgene Expression in AAVS1 Transgenic Mice after in Vivo HSC Transduction with HDAd5/35++ Vectors,” Molecular Therapy 27, no. 12 (2019): 2195–2212.

[135] Z. Li, X. Wang, J. M. Janssen, et al., “Precision Genome Editing Using Combinatorial Viral Vector Delivery of CRISPR-Cas9 Nucleases and Donor DNA Constructs,” Nucleic Acids Research 53, no. 2 (2025): gkae1213.

[136] C. Chamorro, A. Mencia, D. Almarza, et al., “Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes,” Molecular Therapy Nucleic Acids 5, no. 4 (2016): e307.

[137] X. Xu, D. Gao, P. Wang, et al., “Efficient Homology-directed Gene Editing by CRISPR/Cas9 in human Stem and Primary Cells Using Tube Electroporation,” Scientific Reports 8, no. 1 (2018): 11649.

[138] T. Kaneko and T. Mashimo, “Simple Genome Editing of Rodent Intact Embryos by Electroporation,” PloS One 10, no. 11 (2015): e0142755.

[139] G. Ottaviano, C. Georgiadis, S. A. Gkazi, et al., “Phase 1 Clinical Trial of CRISPR-engineered CAR19 Universal T Cells for Treatment of Children with Refractory B Cell Leukemia,” Science Translational Medicine 14, no. 668 (2022): eabq3010.

[140] P. Hoellerbauer, M. Kufeld, and P. J. Paddison, “Efficient Multi-Allelic Genome Editing of Primary Cell Cultures via CRISPR-Cas9 Ribonucleoprotein Nucleofection,” Current Protocols in Stem Cell Biology 54, no. 1 (2020): e126.

[141] Y.-J. Kim, D. Yun, J. K. Lee, C. Jung, and A. J. Chung, “Highly Efficient CRISPR-mediated Genome Editing through Microfluidic Droplet Cell Mechanoporation,” Nature Communications 15, no. 1 (2024): 8099.

[142] X. Xu, C. Liu, S. Wang, et al., “Microfluidic-assisted Biomineralization of CRISPR/Cas9 in near-infrared Responsive Metal–organic Frameworks for Programmable Gene-editing,” Nanoscale 14, no. 42 (2022): 15832–15844.

[143] G. K. Varshney, B. Carrington, and W. Pei, “A High-throughput Functional Genomics Workflow Based on CRISPR/Cas9-mediated Targeted Mutagenesis in Zebrafish,” Nature Protocols 11, no. 12 (2016): 2357–2375.

[144] G. Schlapp, M. N. Meikle, J. L. Pórfido, A. Menchaca, and M. Crispo, “Zygote Cryobanking Applied to CRISPR/Cas9 Microinjection in Mice,” Plos One 19, no. 7 (2024): e0306617.

[145] Q. Chen, X. Wang, Y. Zhang, et al., “Minimizing the Ratio of Ionizable Lipid in Lipid Nanoparticles for in Vivo Base Editing,” National Science Review 11, no. 6 (2024): nwae135.

[146] K. Mrksich, M. S. Padilla, R. A. Joseph, et al., “Influence of Ionizable Lipid Tail Length on Lipid Nanoparticle Delivery of mRNA of Varying Length,” Journal of Biomedical Materials Research Part A 112, no. 9 (2024): 1494–1505.

[147] Y. Lin, M. Li, Z. Luo, et al., “Tissue-specific mRNA Delivery and Prime Editing with Peptide–ionizable Lipid Nanoparticles,” Nature Materials 25, no. 1 (2026): 133–145.

[148] M. Herrera-Barrera, M. Gautam, A. Lokras, K. Vlasova, C. Foged, and G. Sahay, “Lipid Nanoparticle-enabled Intracellular Delivery of Prime Editors,” The AAPS Journal 25, no. 4 (2023): 65.

[149] H. Ju, D. Kim, and Y.-K. Oh, “Lipid Nanoparticle-mediated CRISPR/Cas9 Gene Editing and Metabolic Engineering for Anticancer Immunotherapy,” Asian Journal of Pharmaceutical Sciences 17, no. 5 (2022): 641–652.

[150] S.-Y. Yu, T. Carlaw, T. Thomson, et al., “A Luciferase Reporter Mouse Model to Optimize in Vivo Gene Editing Validated by Lipid Nanoparticle Delivery of Adenine Base Editors,” Molecular Therapy 31, no. 4 (2023): 1159–1166.

[151] Z. Huang, T. Yang, J. Yu, et al., “Ultra-efficient Delivery of CRISPR/Cas9 Using Ionic Liquid Conjugated Polymers for Genome Editing-Based Tumor Therapy,” Biomaterials Science 12, no. 7 (2024): 1716–1725.

[152] X. Zhang, H. Jin, X. Huang, et al., “Robust Genome Editing in Adult Vascular Endothelium by Nanoparticle Delivery of CRISPR-Cas9 Plasmid DNA,” Cell Reports 38, no. 1 (2022): 110196.

[153] R. Ma, Y. Chang, Q. Chen, J. Li, and B. Qiao, “Precise PBAEs: A Highly Efficient Single-molecularly Defined Gene-delivery System,” Angewandte Chemie International Edition 64, no. 19 (2025): e202422134.

[154] Q. Chen, L. Su, X. He, et al., “Poly (beta-amino ester)-Based Nanoparticles Enable Nonviral Delivery of Base Editors for Targeted Tumor Gene Editing,” Biomacromolecules 23, no. 5 (2022): 2116–2125.

[155] X. Wang, Y. Li, J. Lyu, et al., “Cyclization-enhanced Poly (β-amino ester) s Vectors for Efficient CRISPR Gene Editing Therapy,” Journal of Controlled Release 368 (2024): 444–452.

[156] X. Wang, Y. Li, D. Friess, et al., “Guanidyl-rich Highly Branched Poly (β-amino ester) s for the Delivery of Dual CRISPR ribonucleoprotein for Efficient Large DNA Fragment Deletion,” Journal of Controlled Release 379 (2025): 549–557.

[157] H. Zhang, W. Jiang, T. Song, et al., “Lipid-Polymer Nanoparticles Mediate Compartmentalized Delivery of Cas9 and sgRNA for Glioblastoma Vasculature and Immune Reprogramming,” Advanced Science 11, no. 32 (2024): e2309314.

[158] S. Tan, C. Yuan, Y. Zhu, et al., “Glutathione Hybrid Poly (beta-amino ester)-plasmid Nanoparticles for Enhancing Gene Delivery and Biosafety,” Journal of Advanced Research 73 (2025): 697–711.

[159] K. Y. Vlasova, A. Kerr, N. Pennock, et al., “Synthesis of Ionizable Lipopolymers Using Split-Ugi Reaction for Pulmonary Delivery of Various Size RNAs and Gene Editing,” Nature Communications 16, no. 1 (2025): 4021.

[160] Q. Yang, Y. Zhou, J. Chen, N. Huang, Z. Wang, and Y. Cheng, “Gene Therapy for Drug-resistant Glioblastoma via Lipid-polymer Hybrid Nanoparticles Combined with Focused Ultrasound,” International Journal of Nanomedicine 16 (2021): 185–199.

[161] J.-H. Wang, D. J. Gessler, W. Zhan, T. L. Gallagher, and G. Gao, “Adeno-associated Virus as a Delivery Vector for Gene Therapy of human Diseases,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 78.

[162] Y. Lakhina, N. M. Boulis, and A. Donsante, “Current and Emerging Targeted Therapies for Spinal Muscular Atrophy,” Expert Review of Neurotherapeutics 23, no. 12 (2023): 1189–1199.

[163] C.-H. Tai, N.-C. Lee, Y.-H. Chien, et al., “Long-term Efficacy and Safety of Eladocagene Exuparvovec in Patients with AADC Deficiency,” Molecular Therapy 30, no. 2 (2022): 509–518.

[164] E. A. Pierce, T. S. Aleman, K. T. Jayasundera, et al., “Gene Editing for CEP290-associated Retinal Degeneration,” New England Journal of Medicine 390, no. 21 (2024): 1972–1984.

[165] T. H. Burdo, C. Chen, R. Kaminski, et al., “Preclinical Safety and Biodistribution of CRISPR Targeting SIV in Non-human Primates,” Gene Therapy 31, no. 5 (2024): 224–233.

[166] L. Wang, C. Breton, C. C. Warzecha, et al., “Long-term Stable Reduction of Low-density Lipoprotein in Nonhuman Primates Following in Vivo Genome Editing of PCSK9,” Molecular Therapy 29, no. 6 (2021): 2019–2029.

[167] J. Wu, W. Zhao, L. Zhong, et al., “Self-complementary Recombinant Adeno-associated Viral Vectors: Packaging Capacity and the Role of rep Proteins in Vector Purity,” Human Gene Therapy 18, no. 2 (2007): 171–182.

[168] L. F. Barnes, B. E. Draper, Y.-T. Chen, T. W. Powers, and M. F. Jarrold, “Quantitative Analysis of Genome Packaging in Recombinant AAV Vectors by Charge Detection Mass Spectrometry,” Molecular Therapy Methods & Clinical Development 23 (2021): 87–97.

[169] B. T. Assaf, “Systemic Toxicity of Recombinant Adeno-associated Virus Gene Therapy Vectors,” Toxicologic Pathology 52, no. 8 (2024): 523–530.

[170] H. C. Ertl, “Immunogenicity and Toxicity of AAV Gene Therapy,” Frontiers in Immunology 13 (2022): 975803.

[171] A. K. Lam, D. Frabutt, L. Li, and W. Xiao, “Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-associated Virus Vectors,” Human Gene Therapy 32, no. 23-24 (2021): 1433–1438.

[172] M. A. Korneyenkov, “Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification,” Pharmaceutics 13, no. 5 (2021): 750.

[173] L. P. Havlik, K. E. Simon, J. K. Smith, et al., “Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-guided Approach,” Journal of Virology 94, no. 19 (2020): e00976–e01020.

[174] S. R. Kumar, J. Xie, S. Hu, et al., “Coagulation Factor IX Gene Transfer to Non-human Primates Using Engineered AAV3 Capsid and Hepatic Optimized Expression Cassette,” Molecular Therapy Methods & Clinical Development 23 (2021): 98–107.

[175] A. Edraki, A. Mir, R. Ibraheim, et al., “A Compact, High-accuracy Cas9 with a Dinucleotide PAM for in Vivo Genome Editing,” Molecular Cell 73, no. 4 (2019): 714–726. e4.

[176] S. Chen, Z. Liu, W. Xie, H. Yu, L. Lai, and Z. Li, “Compact Cje3Cas9 for Efficient in Vivo Genome Editing and Adenine Base Editing,” The CRISPR Journal 5, no. 3 (2022): 472–486.

[177] S. Kannan, H. Altae-Tran, and X. Jin, “Compact RNA Editors with Small Cas13 Proteins,” Nature Biotechnology 40, no. 2 (2022): 194–197.

[178] A. Geisler, A. Jungmann, J. Kurreck, et al., “microRNA122-regulated Transgene Expression Increases Specificity of Cardiac Gene Transfer Upon Intravenous Delivery of AAV9 Vectors,” Gene Therapy 18, no. 2 (2011): 199–209.

[179] L. Nieland, A. B. Vrijmoet, I. W. Jetten, et al., “CRISPR Targeting of Mmu-miR-21a through a Single Adeno-associated Virus Vector Prolongs Survival of Glioblastoma-bearing Mice,” Molecular Therapy 33, no. 1 (2025): 133–151.

[180] L. F. Earley, L. M. Conatser, V. M. Lue, et al., “Adeno-associated Virus Serotype-specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression,” Human Gene Therapy 31, no. 3-4 (2020): 151–162.

[181] S. Pillay and J. E. Carette, “Host determinants of adeno-associated viral vector entry,” Current Opinion in Virology 24 (2017): 124–131.

[182] M. E. Nonnenmacher, J.-C. Cintrat, D. Gillet, and T. Weber, “Syntaxin 5-dependent Retrograde Transport to the Trans-Golgi Network Is Required for Adeno-associated Virus Transduction,” Journal of Virology 89, no. 3 (2015): 1673–1687.

[183] D. M. McCarty, “Self-complementary AAV Vectors; Advances and Applications,” Molecular Therapy 16, no. 10 (2008): 1648–1656.

[184] L. M. Riedmayr, K. S. Hinrichsmeyer, S. B. Thalhammer, et al., “mRNA Trans-splicing Dual AAV Vectors for (epi) Genome Editing and Gene Therapy,” Nature Communications 14, no. 1 (2023): 6578.

[185] Q. Fu, A. Polanco, Y. S. Lee, and S. Yoon, “Critical Challenges and Advances in Recombinant Adeno-associated Virus (rAAV) Biomanufacturing,” Biotechnology and Bioengineering 120, no. 9 (2023): 2601–2621.

[186] Y. Wang, Q. Fu, S. Y. Park, et al., “Decoding Cellular Mechanism of Recombinant Adeno-associated Virus (rAAV) and Engineering Host-cell Factories toward Intensified Viral Vector Manufacturing,” Biotechnology Advances 71 (2024): 108322.

[187] L. Galibert, A. Jacob, A. Savy, et al., “Monobac System–A Single Baculovirus for the Production of rAAV,” Microorganisms 9, no. 9 (2021): 1799.

[188] Q. Wang, B. Dong, J. Firrman, et al., “Efficient Production of Dual Recombinant Adeno-associated Viral Vectors for Factor VIII Delivery,” Human Gene Therapy Methods (Part B) 25, no. 4 (2014): 261–268.

[189] D.-A. Gross, N. Tedesco, C. Leborgne, and G. Ronzitti, “Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients,” Frontiers in Immunology 13 (2022): 857276.

[190] D. A. Dalwadi, A. Calabria, A. Tiyaboonchai, et al., “AAV Integration in human Hepatocytes,” Molecular Therapy 29, no. 10 (2021): 2898–2909.

[191] D. E. Sabatino, F. D. Bushman, R. J. Chandler, et al., “Evaluating the state of the Science for Adeno-associated Virus Integration: An Integrated Perspective,” Molecular Therapy 30, no. 8 (2022): 2646–2663.

[192] A. Arduini, H. Katiyar, and C. Liang, “Progress in Pseudotyping Lentiviral Vectors towards Cell-specific Gene Delivery in Vivo,” Viruses 17, no. 6 (2025): 802.

[193] P. Kumar and C. Woon-Khiong, “Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications,” Current Gene Therapy 11, no. 2 (2011): 144–153.

[194] W. Dong and B. Kantor, “Lentiviral Vectors for Delivery of Gene-editing Systems Based on CRISPR/Cas: Current state and Perspectives,” Viruses 13, no. 7 (2021): 1288.

[195] W. Xu, J. L. Russ, and M. V. Eiden, “Evaluation of Residual Promoter Activity in γ-retroviral Self-inactivating (SIN) Vectors,” Molecular Therapy 20, no. 1 (2012): 84–90.

[196] H. E. Chick, A. Nowrouzi, R. Fronza, et al., “Integrase-deficient Lentiviral Vectors Mediate Efficient Gene Transfer to human Vascular Smooth Muscle Cells with Minimal Genotoxic Risk,” Human Gene Therapy 23, no. 12 (2012): 1247–1257.

[197] K. Wanisch and R. J. Yanez-Munoz, “Integration-deficient Lentiviral Vectors: A Slow Coming of Age,” Molecular Therapy 17, no. 8 (2009): 1316–1332.

[198] A. Gutierrez-Guerrero, F.-L. Cosset, and E. Verhoeyen, “Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy,” Viruses 12, no. 9 (2020): 1016.

[199] C. Radek, O. Bernadin, K. Drechsel, et al., “Vectofusin-1 Improves Transduction of Primary human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-system Manufacturing,” Human Gene Therapy 30, no. 12 (2019): 1477–1493.

[200] A. Gutierrez-Guerrero, M. J. Abrey Recalde, and P. E. Mangeot, “Baboon Envelope Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in human T, B, and CD34+ Cells and Knock-in of AAV6-encoded Donor DNA in CD34+ Cells,” Frontiers in Genome Editing 3 (2021): 604371.

[201] D. H. Bae, M. Marino, B. Iaffaldano, et al., “Design and Testing of Vector-producing HEK293T Cells Bearing a Genomic Deletion of the SV40 T Antigen Coding Region,” Molecular Therapy Methods & Clinical Development 18 (2020): 631–638.

[202] H. S. Kim, G.-H. Hwang, H. K. Lee, et al., “CReVIS-Seq: A Highly Accurate and Multiplexable Method for Genome-wide Mapping of Lentiviral Integration Sites,” Molecular Therapy Methods & Clinical Development 20 (2021): 792–800.

[203] N. Uchida, C. M. Drysdale, T. Nassehi, et al., “Cas9 protein Delivery Non-integrating Lentiviral Vectors for Gene Correction in Sickle Cell Disease,” Molecular Therapy Methods & Clinical Development 21 (2021): 121–132.

[204] S. V. Bhoopalan, T. Mayuranathan, N. Liu, et al., “Preclinical Development of Lentiviral Vector Gene Therapy for Diamond-Blackfan Anemia Syndrome,” Molecular Therapy 33, no. 7 (2025): 3086–3100.

[205] Z.-D. Shi, J. Tchao, L. Wu, and A. J. Carman, “Precision Installation of a Highly Efficient Suicide Gene Safety Switch in human Induced Pluripotent Stem Cells,” Stem Cells Translational Medicine 9, no. 11 (2020): 1378–1388.

[206] J. Dahlke, J. W. Schott, P. Vollmer Barbosa, et al., “Efficient Genetic Safety Switches for Future Application of iPSC-derived Cell Transplants,” Journal of Personalized Medicine 11, no. 6 (2021): 565.

[207] H. Hayashi, Y. Kubo, M. Izumida, and T. Matsuyama, “Efficient Viral Delivery of Cas9 into human Safe Harbor,” Scientific Reports 10, no. 1 (2020): 21474.

[208] J. Haldrup, S. Andersen, A. R. L. Labial, et al., “Engineered Lentivirus-derived Nanoparticles (LVNPs) for Delivery of CRISPR/Cas ribonucleoprotein Complexes Supporting Base Editing, Prime Editing and in Vivo Gene Modification,” Nucleic Acids Research 51, no. 18 (2023): 10059–10074.

[209] P. Lyu and B. Lu, “New Advances in Using Virus-like Particles and Related Technologies for Eukaryotic Genome Editing Delivery,” International Journal of Molecular Sciences 23, no. 15 (2022): 8750.

[210] M. Hirosawa and H. Saito, “Cell-Type-Specific CRISPR-Cas9 System with miRNAs,” in CRISPR-Cas Methods: Volume 2 (Springer, 2021), 265–279.

[211] J. Lee, H. Mou, R. Ibraheim, et al., “Tissue-restricted Genome Editing in Vivo Specified by microRNA-repressible Anti-CRISPR Proteins,” Rna 25, no. 11 (2019): 1421–1431.

[212] X. Huang, D. Yang, J. Zhang, J. Xu, and Y. E. Chen, “Recent Advances in Improving Gene-editing Specificity through CRISPR–Cas9 Nuclease Engineering,” Cells 11, no. 14 (2022): 2186.

[213] J. Jia, Y. Hao, L. Zhang, et al., “Development and Validation of Optimized Lentivirus-like Particles for Gene Editing Tool Delivery with Gag-Only Strategy,” European Journal of Medical Research 30, no. 1 (2025): 242.

[214] N. Brunetti-Pierri and P. Ng, “Gene Therapy with Helper-dependent Adenoviral Vectors: Lessons from Studies in Large Animal Models,” Virus Genes 53, no. 5 (2017): 684–691.

[215] D. Palmer and P. Ng, “Rescue, Amplification, and Large-scale Production of Helper-dependent Adenoviral Vectors,” Cold Spring Harbor Protocols 2011, no. 7 (2011): 857–866.

[216] D. J. Palmer, D. L. Turner, and P. Ng, “A Single “All-in-one” Helper-dependent adenovirus to Deliver Donor DNA and CRISPR/Cas9 for Efficient Homology-directed Repair,” Molecular Therapy Methods & Clinical Development 17 (2020): 441–447.

[217] S. E. Raper, N. Chirmule, F. S. Lee, et al., “Fatal Systemic Inflammatory Response Syndrome in a Ornithine Transcarbamylase Deficient Patient Following Adenoviral Gene Transfer,” Molecular Genetics and Metabolism 80, no. 1-2 (2003): 148–158.

[218] N. Brunetti-Pierri, T. Ng, D. Iannitti, et al., “Transgene Expression up to 7 Years in Nonhuman Primates Following Hepatic Transduction with Helper-dependent Adenoviral Vectors,” Human Gene Therapy 24, no. 8 (2013): 761–765.

[219] A. C. Nathwani, C. Rosales, J. McIntosh, et al., “Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding human FIX Pseudotyped with Serotype 5 and 8 Capsid Proteins,” Molecular Therapy 19, no. 5 (2011): 876–885.

[220] M. Gonzalez-Aparicio, I. Mauleon, P. Alzuguren, et al., “Self-inactivating Helper Virus for the Production of High-capacity Adenoviral Vectors,” Gene Therapy 18, no. 11 (2011): 1025–1033.

[221] M. Suzuki, R. Cela, C. Clarke, T. K. Bertin, S. Mourino, and B. Lee, “Large-scale Production of High-quality Helper-dependent Adenoviral Vectors Using Adherent Cells in Cell Factories,” Human Gene Therapy 21, no. 1 (2010): 120–126.

[222] C. Li, A. Georgakopoulou, A. Mishra, et al., “In Vivo HSPC Gene Therapy with Base Editors Allows for Efficient Reactivation of Fetal γ-globin in β-YAC Mice,” Blood Advances 5, no. 4 (2021): 1122–1135.

[223] P. C. Freitag, F. Brandl, D. Brucher, F. Weiss, B. Dreier, and A. Pluckthun, “Modular Adapters Utilizing Binders of Different Molecular Types Expand Cell-targeting Options for adenovirus Gene Delivery,” Bioconjugate Chemistry 33, no. 9 (2022): 1595–1601.

[224] A. Jain, G. Zode, R. B. Kasetti, et al., “CRISPR-Cas9–Based Treatment of Myocilin-associated Glaucoma,” Proceedings of the National Academy of Sciences of the United States of America 114, no. 42 (2017): 11199–11204.

[225] S. R. Ng, W. M. Rideout III, E. H. Akama-Garren, et al., “CRISPR-mediated Modeling and Functional Validation of Candidate Tumor Suppressor Genes in Small Cell Lung Cancer,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 1 (2020): 513–521.

[226] A. M. Ngo and A. S. Puschnik, “Genome-scale Analysis of Cellular Restriction Factors That Inhibit Transgene Expression from Adeno-associated Virus Vectors,” Journal of Virology 97, no. 4 (2023): e0194822.

[227] Z. Romero, A. Lomova, S. Said, et al., “Editing the sickle Cell Disease Mutation in human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates,” Molecular Therapy 27, no. 8 (2019): 1389–1406.

[228] B. H. Yip, “Recent advances in CRISPR/Cas9 delivery strategies,” Biomolecules 10, no. 6 (2020): 839.

[229] T. V. Mashel, Y. V. Tarakanchikova, A. R. Muslimov, et al., “Overcoming the Delivery Problem for Therapeutic Genome Editing: Current Status and Perspective of Non-viral Methods,” Biomaterials 258 (2020): 120282.

[230] T. Kotnik, L. Rems, M. Tarek, and D. Miklavčič, “Membrane Electroporation and Electropermeabilization: Mechanisms and Models,” Annual Review of Biophysics 48, no. 1 (2019): 63–91.

[231] P. Kumar, A. Nagarajan, and P. D. Uchil, “Electroporation,” Cold Spring Harbor Protocols 2019, no. 7 (2019): top096271.

[232] T. S. Santra, P.-C. Wang, and F. G. Tseng, “Electroporation Based Drug Delivery and Its applications,” in Advances in Micro/Nano Electromechanical Systems and Fabrication Technologies (2013), 61–98.

[233] A. Nikyar and A. Bolhassani, “Electroporation: An Effective Method for in Vivo Gene Delivery,” Drug Delivery Letters 12, no. 1 (2022): 35–45.

[234] D. Zhao, D. Huang, Y. Li, et al., “A Flow-through Cell Electroporation Device for Rapidly and Efficiently Transfecting Massive Amounts of Cells in Vitro and Ex Vivo,” Scientific Reports 6, no. 1 (2016): 18469.

[235] H. Kim, M. Lee, B. Han, et al., “Advancing allogeneic NK cell immunotherapy through microfluidic gene delivery,” Advanced Science 12, no. 17 (2025): e2412544.

[236] B. J. Sytsma, V. Allain, S. Bourke, et al., “Scalable Intracellular Delivery via Microfluidic Vortex Shedding Enhances the Function of Chimeric Antigen Receptor T-cells,” Scientific Reports 15, no. 1 (2025): 5749.

[237] J. A. VanderBurgh, T. N. Corso, S. L. Levy, and H. G. Craighead, “Scalable Continuous-flow Electroporation Platform Enabling T Cell Transfection for Cellular Therapy Manufacturing,” Scientific Reports 13, no. 1 (2023): 6857.

[238] R. Ren, J. Guo, G. Liu, et al., “Nucleic Acid Direct Delivery to Fibroblasts: A Review of Nucleofection and Applications,” Journal of Biological Engineering 16, no. 1 (2022): 30.

[239] F. Agostini, C. Vicinanza, G. Biolo, et al., “Nucleofection of Adipose Mesenchymal Stem/Stromal Cells: Improved Transfection Efficiency for GMP Grade Applications,” Cells 10, no. 12 (2021): 3412.

[240] D. Sevenler and M. Toner, “High Throughput Intracellular Delivery by Viscoelastic Mechanoporation,” Nature Communications 15, no. 1 (2024): 115.

[241] A. R. Kumar, J. Low, J. Lim, et al., “Non-viral, High Throughput Genetic Engineering of Primary Immune Cells Using Nanostraw-mediated Transfection,” Biomaterials 317 (2025): 123079.

[242] X. Liu, J. Jiang, J. Liu, et al., “Nanoneedle Array-electroporation Facilitates Intranuclear ribonucleoprotein Delivery and High Throughput Gene Editing,” Advanced Healthcare Materials 13, no. 29 (2024): e2400645.

[243] R. Xiong, D. Hua, J. Van Hoeck, et al., “Photothermal Nanofibres Enable Safe Engineering of Therapeutic Cells,” Nature Nanotechnology 16, no. 11 (2021): 1281–1291.

[244] E. Moses, R. Franek, and I. Harel, “A Scalable and Tunable Platform for Functional Interrogation of Peptide Hormones in Fish,” Elife 12 (2023): e85960.

[245] T. Suda, T. Yokoo, T. Kanefuji, K. Kamimura, G. Zhang, and D. Liu, “Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances,” Pharmaceutics 15, no. 4 (2023): 1111.

[246] L. Sendra, M. J. Herrero, and S. F. Aliño, “Translational Advances of Hydrofection by Hydrodynamic Injection,” Genes 9, no. 3 (2018): 136.

[247] F. Chen, M. Alphonse, and Q. Liu, “Strategies for Nonviral Nanoparticle-Based Delivery of CRISPR/Cas9 Therapeutics,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 12, no. 3 (2020): e1609.

[248] N. Aliakbarinodehi, S. Niederkofler, G. Emilsson, et al., “Time-resolved Inspection of Ionizable Lipid-facilitated Lipid Nanoparticle Disintegration and Cargo Release at an Early Endosomal Membrane Mimic,” ACS Nano 18, no. 34 (2024): 22989–23000.

[249] K. Rajappan, S. P. Tanis, R. Mukthavaram, et al., “Property-driven Design and Development of Lipids for Efficient Delivery of siRNA,” Journal of Medicinal Chemistry 63, no. 21 (2020): 12992–13012.

[250] D. Adams, A. Gonzalez-Duarte, W. D. O'Riordan, et al., “Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis,” New England Journal of Medicine 379, no. 1 (2018): 11–21.

[251] K.-P. Lin, C.-C. Yang, Y.-C. Lee, et al., “Patisiran, an RNAi Therapeutic for Hereditary Transthyretin-mediated Amyloidosis: Sub-analysis in Taiwanese Patients from the APOLLO Study,” Journal of the Formosan Medical Association 123, no. 9 (2024): 975–984.

[252] M. Pesce, D. R. Feikin, M. M. Higdon, et al., “Global Disparities in the Introduction, Scale-up, and Effectiveness Evaluation of COVID-19 Vaccines,” Nature Communications 16, no. 1 (2025): 9059.

[253] K. Walsh, P. Cottingham, C. Shaw, et al., “CRISPR/Cas9-mediated KLKB1 Gene Editing and Serum Kallikrein Reduction by NTLA-2002 Remains Durable in Humanized Mice Following Liver Regeneration after Partial Hepatectomy,” Journal of Allergy and Clinical Immunology 149, no. 2 (2022): AB169.

[254] Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard, and D. J. Siegwart, “Selective Organ Targeting (SORT) Nanoparticles for Tissue-specific mRNA Delivery and CRISPR–Cas Gene Editing,” Nature Nanotechnology 15, no. 4 (2020): 313–320.

[255] S. A. Dilliard, Q. Cheng, and D. J. Siegwart, “On the Mechanism of Tissue-specific mRNA Delivery by Selective Organ Targeting Nanoparticles,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 52 (2021): e2109256118.

[256] L. Xue, X. Xiong, G. Zhao, et al., “Multiarm-assisted Design of Dendron-like Degradable Ionizable Lipids Facilitates Systemic mRNA Delivery to the Spleen,” Journal of the American Chemical Society 147, no. 2 (2025): 1542–1552.

[257] Z. Chen, Y. Yang, X. Qiu, H. Zhou, R. Wang, and H. Xiong, “Crown-like Biodegradable Lipids Enable Lung-selective mRNA Delivery and Dual-modal Tumor Imaging in Vivo,” Journal of the American Chemical Society 146, no. 49 (2024): 34209–34220.

[258] R. Zhang, R. El-Mayta, T. J. Murdoch, et al., “Helper Lipid Structure Influences Protein Adsorption and Delivery of Lipid Nanoparticles to Spleen and Liver,” Biomaterials Science 9, no. 4 (2021): 1449–1463.

[259] A. Vaidya, S. Moore, S. Chatterjee, et al., “Expanding RNAi to Kidneys, Lungs, and Spleen via Selective ORgan Targeting (SORT) siRNA Lipid Nanoparticles,” Advanced Materials 36, no. 35 (2024): e2313791.

[260] Y. Lin, E. Wagner, and U. Lächelt, “Non-viral Delivery of the CRISPR/Cas System: DNA versus RNA versus RNP,” Biomaterials Science 10, no. 5 (2022): 1166–1192.

[261] H. Onuma, R. Shimizu, Y. Suzuki, M. Sato, H. Harashima, and Y. Sato, “Engineering Branched Ionizable Lipid for Hepatic Delivery of Clustered Regularly Interspaced Short Palindromic Repeat-Cas9 Ribonucleoproteins,” iScience 27, no. 10 (2024): 110928.

[262] R. Palanki, J. S. Riley, S. K. Bose, et al., “In Utero Delivery of Targeted Ionizable Lipid Nanoparticles Facilitates in Vivo Gene Editing of Hematopoietic Stem Cells,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 32 (2024): e2400783121.

[263] R. Palanki, E. L. Han, and A. M. Murray, “Optimized Microfluidic Formulation and Organic Excipients for Improved Lipid Nanoparticle Mediated Genome Editing,” Lab on a Chip 24, no. 16 (2024): 3790–3801.

[264] Q. Tang, J. Liu, Y. Jiang, M. Zhang, L. Mao, and M. Wang, “Cell-selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-derived Lipid Nanoparticles and Cellular Surface Sialic Acid,” ACS Applied Materials & Interfaces 11, no. 50 (2019): 46585–46590.

[265] Y. Xu, F. Gong, A. Golubovic, et al., “Rational Design and Modular Synthesis of Biodegradable Ionizable Lipids via the Passerini Reaction for mRNA Delivery,” Proceedings of the National Academy of Sciences of the United States of America 122, no. 5 (2025): e2409572122.

[266] M. S. Padilla, K. Mrksich, Y. Wang, et al., “Branched Endosomal Disruptor (BEND) Lipids Mediate Delivery of mRNA and CRISPR-Cas9 ribonucleoprotein Complex for Hepatic Gene Editing and T Cell Engineering,” Nature Communications 16, no. 1 (2025): 996.

[267] L. R. Baden, H. M. El Sahly, and B. Essink, “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,” New England Journal of Medicine 384, no. 5 (2021): 403–416.

[268] V. Francia, R. M. Schiffelers, P. R. Cullis, and D. Witzigmann, “The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy,” Bioconjugate Chemistry 31, no. 9 (2020): 2046–2059.

[269] K. Yang, B. Mesquita, P. Horvatovich, and A. Salvati, “Tuning Liposome Composition to Modulate Corona Formation in human Serum and Cellular Uptake,” Acta Biomaterialia 106 (2020): 314–327.

[270] H. Tang, Y. Zhang, T. Yang, et al., “Cholesterol Modulates the Physiological Response to Nanoparticles by Changing the Composition of Protein Corona,” Nature Nanotechnology 18, no. 9 (2023): 1067–1077.

[271] V. M. Olkkonen, H. Gylling, and E. Ikonen, “Plant Sterols, Cholesterol Precursors and Oxysterols: Minute Concentrations—Major Physiological Effects,” The Journal of Steroid Biochemistry and Molecular Biology 169 (2017): 4–9.

[272] C. X. Foo, S. Bartlett, and K. Ronacher, “Oxysterols in the Immune Response to Bacterial and Viral Infections,” Cells 11, no. 2 (2022): 201.

[273] M. F. Osborn, A. H. Coles, A. Biscans, et al., “Hydrophobicity Drives the Systemic Distribution of Lipid-conjugated siRNAs via Lipid Transport Pathways,” Nucleic Acids Research 47, no. 3 (2019): 1070–1081.

[274] M. F. Osborn and A. Khvorova, “Improving siRNA Delivery in Vivo through Lipid Conjugation,” Nucleic Acid Therapeutics 28, no. 3 (2018): 128–136.

[275] D. Pozzi, V. Colapicchioni, G. Caracciolo, et al., “Effect of Polyethyleneglycol (PEG) Chain Length on the Bio–nano-interactions between PEGylated Lipid Nanoparticles and Biological Fluids: From Nanostructure to Uptake in Cancer Cells,” Nanoscale 6, no. 5 (2014): 2782–2792.

[276] N. Saber, M. E. Senti, and R. M. Schiffelers, “Lipid Nanoparticles for Nucleic Acid Delivery beyond the Liver,” Human Gene Therapy 35, no. 17-18 (2024): 617–627.

[277] S. D. Li and L. Huang, “Stealth Nanoparticles: High Density but Sheddable PEG Is a Key for Tumor Targeting,” J Control Release 145, no. 3 (2010): 178–181.

[278] N. Aliakbarinodehi, A. Gallud, M. Mapar, et al., “Interaction Kinetics of Individual mRNA-containing Lipid Nanoparticles with an Endosomal Membrane Mimic: Dependence on pH, Protein Corona Formation, and Lipoprotein Depletion,” ACS Nano 16, no. 12 (2022): 20163–20173.

[279] R. Cai, J. Ren, M. Guo, et al., “Dynamic Intracellular Exchange of Nanomaterials' protein Corona Perturbs Proteostasis and Remodels Cell Metabolism,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 23 (2022): e2200363119.

[280] D. van Straten, H. Sork, L. van de Schepop, R. Frunt, K. Ezzat, and R. M. Schiffelers, “Biofluid Specific Protein Coronas Affect Lipid Nanoparticle Behavior in Vitro,” Journal of Controlled Release 373 (2024): 481–492.

[281] X. Huang, Y. Ma, G. Ma, and Y. Xia, “Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies,” Research 7 (2024): 0370.

[282] I. Isaac, L. Patel, D. Yun, S. Park, and C. Bhattacharya, “Endogenous Corticosteroid Derived Lipid Nanoparticles (cortico LNPs) Enable Selective mRNA Delivery to the Spleen,” Small 21, no. 36 (2025): e03034.

[283] J. E. Dahlman, K. J. Kauffman, Y. Xing, et al., “Barcoded Nanoparticles for High Throughput in Vivo Discovery of Targeted Therapeutics,” Proceedings of the National Academy of Sciences of the United States of America 114, no. 8 (2017): 2060–2065.

[284] M. Kim, Y. Pyo, S.-I. Hyun, M. Jeong, Y. Choi, and V. N. Kim, “Exogenous RNA Surveillance by Proton-sensing TRIM25,” Science 388, no. 6742 (2025): eads4539.

[285] Q. Sun, H. Zhang, F. Ding, X. Gao, Z. Zhu, and C. Yang, “Development of Ionizable Lipid Nanoparticles and a Lyophilized Formulation for Potent CRISPR-Cas9 Delivery and Genome Editing,” International Journal of Pharmaceutics 652 (2024): 123845.

[286] Z. Chen, Y. Tian, J. Yang, et al., “Modular Design of Biodegradable Ionizable Lipids for Improved mRNA Delivery and Precise Cancer Metastasis Delineation in Vivo,” Journal of the American Chemical Society 145, no. 44 (2023): 24302–24314.

[287] S. Liu, Q. Cheng, T. Wei, et al., “Membrane-destabilizing Ionizable Phospholipids for Organ-selective mRNA Delivery and CRISPR–Cas Gene Editing,” Nature Materials 20, no. 5 (2021): 701–710.

[288] E. S. Hosseini, M. Nikkhah, and S. Hosseinkhani, “Cholesterol-rich Lipid-mediated Nanoparticles Boost of Transfection Efficiency, Utilized for Gene Editing by CRISPR-Cas9,” International Journal of Nanomedicine 14 (2019): 4353–4366.

[289] D. A. Rodríguez, G. P. Lefebvre, Q. Yang, et al., “Incorporation of Cellular Membrane Protein Extracts into Lipid Nanoparticles Enhances Their Cellular Uptake and mRNA Delivery Efficiency,” Journal of Controlled Release 382 (2025): 113676.

[290] L. Ren, Z. Zhao, Y. Chao, et al., “Optimization of Lipid Nanoparticles with Robust Efficiency for the Delivery of Protein Therapeutics to Augment Cancer Immunotherapy,” Advanced Science 12, no. 17 (2025): e2500844.

[291] H. Kong, C. Zheng, K. Yi, et al., “An Antifouling Membrane-fusogenic Liposome for Effective Intracellular Delivery in Vivo,” Nature Communications 15, no. 1 (2024): 4267.

[292] L. Qiu, M. Sun, L. Chen, et al., “Iron-Confined CRISPR/Cas9-Ribonucleoprotein Delivery System for Redox-Responsive Gene Editing,” Small 20, no. 30 (2024): e2309431.

[293] P. J. Chen, J. A. Hussmann, J. Yan, et al., “Enhanced Prime Editing Systems by Manipulating Cellular Determinants of Editing Outcomes,” Cell 184, no. 22 (2021): 5635–5652. e29.

[294] Y. Sun, X. Xu, L. Chen, W. L. Chew, Y. Ping, and A. Miserez, “Redox-responsive Phase-separating Peptide as a Universal Delivery Vehicle for CRISPR/Cas9 Genome Editing Machinery,” ACS Nano 17, no. 17 (2023): 16597–16606.

[295] J. P. Beyersdorf, S. Bawage, N. Iglesias, et al., “Robust, Durable Gene Activation in Vivo via mRNA-encoded Activators,” ACS Nano 16, no. 4 (2022): 5660–5671.

[296] D. A. Sousa, R. Gaspar, C. J. Ferreira, F. Baltazar, L. R. Rodrigues, and B. F. Silva, “In Vitro CRISPR/Cas9 Transfection and Gene-editing Mediated by Multivalent Cationic Liposome–DNA Complexes,” Pharmaceutics 14, no. 5 (2022): 1087.

[297] R. Xie, X. Wang, Y. Wang, et al., “pH-responsive Polymer Nanoparticles for Efficient Delivery of Cas9 ribonucleoprotein with or without Donor DNA,” Advanced Materials 34, no. 23 (2022): e2110618.

[298] S. K. Cho, R. T. Lee, Y. H. Hwang, and Y. J. Kwon, “Chemically Tuned Intracellular Gene Delivery by Core-Shell Nanoparticles: Effects of Proton Buffering, Acid Degradability, and Membrane Disruption,” ChemMedChem 17, no. 7 (2022): e202100718.

[299] X. Li, C. Omonova Tuychi Qizi, A. Mohamed Khamis, C. Zhang, and Z. Su, “Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells: Li, Omonova Tuychi qizi, Mohamed Khamis, Zhang and Su,” Pharmaceutical Research 39, no. 6 (2022): 1065–1083.

[300] H. Liu, H. Wang, W. Yang, and Y. Cheng, “Disulfide Cross-linked Low Generation Dendrimers with High Gene Transfection Efficacy, Low Cytotoxicity, and Low Cost,” Journal of the American Chemical Society 134, no. 42 (2012): 17680–17687.

[301] T. Zhao, H. Zhang, B. Newland, A. Aied, D. Zhou, and W. Wang, “Significance of Branching for Transfection: Synthesis of Highly Branched Degradable Functional Poly (dimethylaminoethyl methacrylate) by Vinyl Oligomer Combination,” Angewandte Chemie 126, no. 24 (2014): 6209–6214.

[302] N. Bono, F. Ponti, D. Mantovani, and G. Candiani, “Non-viral in Vitro Gene Delivery: It Is Now Time to Set the Bar!,” Pharmaceutics 12, no. 2 (2020): 183.

[303] B. Saqafi and F. Rahbarizadeh, “Effect of PEI Surface Modification with PEG on Cytotoxicity and Transfection Efficiency,” Micro & Nano Letters 13, no. 8 (2018): 1090–1095.

[304] K. Chauhan, J. Woo, W. Jung, and K. D.-E. Poly, “(ethylene Glycol)-engrafted Graphene Oxide for Gene Delivery and Nucleic Acid Amplification,” Materials 16, no. 23 (2023): 7434.

[305] J. Karlsson, K. R. Rhodes, J. J. Green, and S. Y. Tzeng, “Poly (beta-amino ester) s as Gene Delivery Vehicles: Challenges and Opportunities,” Expert Opinion on Drug Delivery 17, no. 10 (2020): 1395–1410.

[306] E. W. Kavanagh, S. Y. Tzeng, N. Sharma, G. R. Cutting, and J. J. Green, “Ligand-free Biodegradable Poly (beta-amino ester) Nanoparticles for Targeted Systemic Delivery of mRNA to the Lungs,” Biomaterials 313 (2025): 122753.

[307] S. Liu, Y. Gao, and S.A , “Biodegradable Highly Branched Poly (β-amino ester) s for Targeted Cancer Cell Gene Transfection,” ACS Biomaterials Science & Engineering 3, no. 7 (2017): 1283–1286.

[308] F. Xu, Z. Zhang, Y. Ping, J. Li, E. Kang, and K. Neoh, “Star-shaped Cationic Polymers by Atom Transfer Radical Polymerization from β-cyclodextrin Cores for Nonviral Gene Delivery,” Biomacromolecules 10, no. 2 (2009): 285–293.

[309] T. Ahmed, F.-C. F. Liu, and X. Y. Wu, “An Update on Strategies for Optimizing Polymer-lipid Hybrid Nanoparticle-mediated Drug Delivery: Exploiting Transformability and Bioactivity of PLN and Harnessing Intracellular Lipid Transport Mechanism,” Expert Opinion on Drug Delivery 21, no. 2 (2024): 245–278.

[310] O. F. Khan, P. S. Kowalski, J. C. Doloff, et al., “Endothelial siRNA Delivery in Nonhuman Primates Using Ionizable Low–molecular Weight Polymeric Nanoparticles,” Science Advances 4, no. 6 (2018): eaar8409.

[311] J. E. Dahlman, C. Barnes, O. F. Khan, et al., “In Vivo Endothelial siRNA Delivery Using Polymeric Nanoparticles with Low Molecular Weight,” Nature Nanotechnology 9, no. 8 (2014): 648–655.

[312] X. Zhao, X. Li, Y. Zhao, et al., “Immune Activities of Polycationic Vectors for Gene Delivery,” Frontiers in Pharmacology 8 (2017): 510.

[313] J. I. Bowman, J. B. Young, V. L. Thompson, et al., “Oxidative Polymer Degradation via Cope Elimination,” Macromolecules 57, no. 15 (2024): 7547–7555.

[314] C. Wang, T. Zeng, C. Gu, S. Zhu, Q. Zhang, and X. Luo, “Photodegradation Pathways of Typical Phthalic Acid Esters under UV, UV/TiO2, and UV-Vis/Bi2WO6 Systems,” Frontiers in Chemistry 7 (2019): 852.

[315] S. Nimesh and R. Chandra, “Guanidinium-grafted Polyethylenimine: An Efficient Transfecting Agent for Mammalian Cells,” European Journal of Pharmaceutics and Biopharmaceutics 68, no. 3 (2008): 647–655.

[316] A. Dehshahri, R. K. Oskuee, W. T. Shier, A. Hatefi, and M. Ramezani, “Gene Transfer Efficiency of High Primary Amine Content, Hydrophobic, Alkyl-oligoamine Derivatives of Polyethylenimine,” Biomaterials 30, no. 25 (2009): 4187–4194.

[317] L. M. Bools, R. K. Fisher, O. H. Grandas, et al., “Comparative Analysis of Polymers for Short Interfering RNA Delivery in Vascular Smooth Muscle Cells,” Journal of Surgical Research 199, no. 1 (2015): 266–273.

[318] A. Mohanty, S. Uthaman, and I.-K. Park, “Utilization of Polymer-lipid Hybrid Nanoparticles for Targeted Anti-cancer Therapy,” Molecules 25, no. 19 (2020): 4377.

[319] W. Liyanage, G. R. Kannan, S. Kannan, and R. M. Kannan, “Efficient Intracellular Delivery of CRISPR-Cas9 Ribonucleoproteins Using Dendrimer Nanoparticles for Robust Genomic Editing,” Nano Today 61 (2025): 102654.

[320] C. Yuan, S. Chang, C. Zhang, et al., “Post Cross-linked ROS-responsive Poly (β-amino ester)-plasmid Polyplex NPs for Gene Therapy of EBV-associated Nasopharyngeal Carcinoma,” Journal of Materials Chemistry B 12, no. 12 (2024): 3129–3143.

[321] X. Gao, D. Dong, C. Zhang, et al., “Chitosan-functionalized Poly (β-amino ester) Hybrid System for Gene Delivery in Vaginal Mucosal Epithelial Cells,” Pharmaceutics 16, no. 1 (2024): 154.

[322] A. M. Weiss, M. A. Lopez, B. W. Rawe, et al., “Understanding How Cationic Polymers' properties Inform Toxic or Immunogenic Responses via Parametric Analysis,” Macromolecules 56, no. 18 (2023): 7286–7299.

[323] H. Zhao, C. Zhang, C. Tian, et al., “Rational Design of Diblock Copolymer Enables Efficient Cytosolic Protein Delivery,” Journal of Colloid and Interface Science 673 (2024): 722–734.

[324] Y. Liu, F. Li, Y. Lyu, et al., “A Semiconducting Polymer nanoCRISPR for near-infrared Photoactivatable Gene Editing and Cancer Gene Therapy,” Nano Letters 25, no. 11 (2025): 4518–4525.

[325] M. Zhang, X. Lu, L. Luo, et al., “Targeting Glutamine Synthetase with AS1411-modified Exosome-liposome Hybrid Nanoparticles for Inhibition of Choroidal Neovascularization,” Journal of Nanobiotechnology 22, no. 1 (2024): 703.

[326] A. Ghaemi, K. Abnous, S. M. Taghdisi, M. Vakili-Azghandi, M. Ramezani, and M. Alibolandi, “Robust Aptamer-targeted CRISPR/Cas9 Delivery Using Mesenchymal Stem Cell Membrane–liposome Hybrid: BIRC5 Gene Knockout against Melanoma,” Nanomedicine: Nanotechnology, Biology and Medicine 62 (2024): 102778.

[327] K. Wu, M. He, B. Mao, et al., “Enhanced Delivery of CRISPR/Cas9 System Based on Biomimetic Nanoparticles for hepatitis B Virus Therapy,” Journal of Controlled Release 374 (2024): 293–311.

[328] K. Ling, Y. Dou, N. Yang, et al., “Genome Editing mRNA Nanotherapies Inhibit Cervical Cancer Progression and Regulate the Immunosuppressive Microenvironment for Adoptive T-cell Therapy,” Journal of Controlled Release 360 (2023): 496–513.

[329] Y. Hu, B. Lu, Z. Deng, F. Xing, and W. Hsu, “Virus-like Particle-Based Delivery of Cas9/Guide RNA ribonucleoprotein Efficiently Edits the Brachyury Gene and Inhibits Chordoma Growth in Vivo,” Discover Oncology 14, no. 1 (2023): 70.

[330] J. Liu, J. Chang, Y. Jiang, et al., “Fast and Efficient CRISPR/Cas9 Genome Editing in Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles,” Advanced Materials 31, no. 33 (2019): e1902575.

[331] M. Yadav, A. Atala, and B. Lu, “Developing All-in-one Virus-like Particles for Cas9 mRNA/Single Guide RNA co-delivery and Aptamer-containing Lentiviral Vectors for Improved Gene Expression,” International journal of biological macromolecules 209 (2022): 1260–1270.

[332] M. Segel, B. Lash, J. Song, et al., “Mammalian Retrovirus-like Protein PEG10 Packages Its Own mRNA and Can be Pseudotyped for mRNA Delivery,” Science 373, no. 6557 (2021): 882–889.

[333] K. Riecken, D. Głów, and B. Fehse, “How to Package and SEND mRNA: A Novel “Humanized” Vector System Based on Endogenous Retroviruses,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 384.

[334] J. Choi, Y. Dang, S. Abraham, et al., “Lentivirus Pre-packed with Cas9 Protein for Safer Gene Editing,” Gene Therapy 23, no. 7 (2016): 627–633.

[335] J. R. Hamilton, C. A. Tsuchida, D. N. Nguyen, et al., “Targeted Delivery of CRISPR-Cas9 and Transgenes Enables Complex Immune Cell Engineering,” Cell Reports 35, no. 9 (2021): 109207.

[336] M. An, A. Raguram, S. W. Du, et al., “Engineered Virus-like Particles for Transient Delivery of Prime Editor ribonucleoprotein Complexes in Vivo,” Nature Biotechnology 42, no. 10 (2024): 1526–1537.

[337] J. Kreitz, M. J. Friedrich, A. Guru, et al., “Programmable Protein Delivery with a Bacterial Contractile Injection System,” Nature 616, no. 7956 (2023): 357–364.

[338] J. Kreitz, V. Yang, M. J. Friedrich, J. Pham, R. K. Macrae, and F. Zhang, “Targeted Delivery of Diverse Biomolecules with Engineered Bacterial Nanosyringes,” Nature Biotechnology (2025): 1–5.

[339] Y. Ye, X. Zhang, F. Xie, et al., “An Engineered Exosome for Delivering sgRNA: Cas9 ribonucleoprotein Complex and Genome Editing in Recipient Cells,” Biomaterials Science 8, no. 10 (2020): 2966–2976.

[340] P. Gee, M. S. Lung, Y. Okuzaki, et al., “Extracellular Nanovesicles for Packaging of CRISPR-Cas9 Protein and sgRNA to Induce Therapeutic Exon Skipping,” Nature Communications 11, no. 1 (2020): 1334.

[341] Y. Wan, L. Li, R. Chen, et al., “Engineered Extracellular Vesicles Efficiently Deliver CRISPR-Cas9 ribonucleoprotein (RNP) to Inhibit herpes Simplex virus1 Infection in Vitro and in Vivo,” Acta Pharmaceutica Sinica B 14, no. 3 (2024): 1362–1379.

[342] Q. Wang, J. Yu, T. Kadungure, J. Beyene, H. Zhang, and Q. Lu, “ARMMs as a Versatile Platform for Intracellular Delivery of Macromolecules,” Nature Communications 9, no. 1 (2018): 960.

[343] Z. Chen, Q. Wang, and Q. Lu, “Engineering ARMMs for Improved Intracellular Delivery of CRISPR-Cas9,” Extracellular Vesicle 5 (2025): 100082.

[344] L. A. Campbell, L. M. Coke, C. T. Richie, L. V. Fortuno, A. Y. Park, and B. K. Harvey, “Gesicle-mediated Delivery of CRISPR/Cas9 ribonucleoprotein Complex for Inactivating the HIV Provirus,” Molecular Therapy 27, no. 1 (2019): 151–163.

[345] X. Zhang, Q. Xu, Z. Zi, et al., “Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications,” Developmental Cell 55, no. 6 (2020): 784–801. e9.

[346] S. Krishnamurthy, C. Wohlford-Lenane, S. Kandimalla, et al., “Engineered Amphiphilic Peptides Enable Delivery of Proteins and CRISPR-associated Nucleases to Airway Epithelia,” Nature Communications 10, no. 1 (2019): 4906.

[347] O. Gustafsson, J. Rädler, S. Roudi, et al., “Efficient Peptide-mediated in Vitro Delivery of Cas9 RNP,” Pharmaceutics 13, no. 6 (2021): 878.

[348] K. E. Shalaby, M. Aouida, V. Gupta, H. Abdesselem, and O. M. El-Agnaf, “Development of Non-viral Vectors for Neuronal-targeted Delivery of CRISPR-Cas9 RNA-proteins as a Therapeutic Strategy for Neurological Disorders,” Biomaterials Science 10, no. 17 (2022): 4959–4977.

[349] V. G. Gonzalez, A. Grunenberger, O. Nicoud, et al., “Enhanced CRISPR-Cas9 RNA System Delivery Using Cell Penetrating Peptides-Based Nanoparticles for Efficient in Vitro and in Vivo Applications,” Journal of Controlled Release 376 (2024): 1160–1175.

[350] K. Chen, E. C. Stahl, M. H. Kang, et al., “Engineering Self-deliverable Ribonucleoproteins for Genome Editing in the Brain,” Nature Communications 15, no. 1 (2024): 1727.

[351] J. P. Graham, J. G. Castro, L. C. Werba, et al., “Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells,” Advanced Functional Materials 36, no. 5 (2026): e01532.

[352] T. Del'Guidice, J.-P. Lepetit-Stoffaes, L.-J. Bordeleau, et al., “Membrane Permeabilizing Amphiphilic Peptide Delivers Recombinant Transcription Factor and CRISPR-Cas9/Cpf1 Ribonucleoproteins in Hard-to-modify Cells,” PloS One 13, no. 4 (2018): e0195558.

[353] M. Li, S. Zhou, S. Zhang, et al., “Transdermal Delivery of CRISPR/Cas9-mediated Melanoma Gene Therapy via Polyamines-modified Thermosensitive Hydrogels,” Journal of Nanobiotechnology 23, no. 1 (2025): 441.

[354] X.-J. Yu, Y.-T. Zhao, H. Abudouaini, et al., “A Novel Spherical GelMA-HAMA Hydrogel Encapsulating APET× 2 Polypeptide and CFIm25-targeting sgRNA for Immune Microenvironment Modulation and Nucleus Pulposus Regeneration in Intervertebral Discs,” Journal of Nanobiotechnology 22, no. 1 (2024): 556.

[355] T.-C. Ho, H. S. Kim, Y. Chen, et al., “Scaffold-mediated CRISPR-Cas9 Delivery System for Acute Myeloid Leukemia Therapy,” Science Advances 7, no. 21 (2021): eabg3217.

[356] S. Rohiwal, N. Dvorakova, J. Klima, et al., “Polyethylenimine Based Magnetic Nanoparticles Mediated Non-viral CRISPR/Cas9 System for Genome Editing,” Scientific Reports 10, no. 1 (2020): 4619.

[357] H. Y. Cho, M. Yoo, T. Pongkulapa, et al., “Magnetic Nanoparticle-Assisted Non-Viral CRISPR-Cas9 for Enhanced Genome Editing to Treat Rett Syndrome,” Advanced Science 11, no. 24 (2024): e2306432.

[358] T. Wan, J. Zhong, Q. Pan, T. Zhou, Y. Ping, and X. Liu, “Exosome-mediated Delivery of Cas9 ribonucleoprotein Complexes for Tissue-specific Gene Therapy of Liver Diseases,” Science Advances 8, no. 37 (2022): eabp9435.

[359] C. E. M. de Morais CCPdL, M. H. Bonamino, and V. ZFMd, “Cell-penetrating Peptides and Crispr-cas9: A Combined Strategy for human Genetic Disease Therapy,” Human Gene Therapy 35, no. 19-20 (2024): 781–797.

[360] S. C. Emencheta, A. L. Onugwu, C. F. Kalu, et al., “Bacteriophages as Nanocarriers for Targeted Drug Delivery and Enhanced Therapeutic Effects,” Materials Advances 5, no. 3 (2024): 986–1016.

[361] W. Ngo, J. Peukes, A. Baldwin, et al., “Mechanism-guided Engineering of a Minimal Biological Particle for Genome Editing,” Proceedings of the National Academy of Sciences of the United States of America 122, no. 1 (2025): e2413519121.

[362] A. Prel, V. Caval, R. Gayon, et al., “Highly Efficient in Vitro and in Vivo Delivery of Functional RNAs Using New Versatile MS2-chimeric Retrovirus-like Particles,” Molecular Therapy Methods & Clinical Development 2 (2015): 15039.

[363] B. Lu, P. Javidi-Parsijani, V. Makani, et al., “Delivering SaCas9 mRNA by Lentivirus-like Bionanoparticles for Transient Expression and Efficient Genome Editing,” Nucleic Acids Research 47, no. 8 (2019): e44.

[364] M. Li, Z. Liu, D. Wang, et al., “Intraocular mRNA Delivery with Endogenous MmPEG10-Based Virus-like Particles,” Experimental Eye Research 243 (2024): 109899.

[365] P. Ge, D. Scholl, N. S. Prokhorov, et al., “Action of a Minimal Contractile Bactericidal Nanomachine,” Nature 580, no. 7805 (2020): 658–662.

[366] L. Lin, “The Expanding Universe of Contractile Injection Systems in Bacteria,” Current Opinion in Microbiology 79 (2024): 102465.

[367] A. H. Berggreen, J. L. Petersen, L. Lin, K. Benabdellah, and Y. Luo, “CRISPR Delivery with Extracellular Vesicles: Promises and Challenges,” Journal of Extracellular Biology 2, no. 9 (2023): e111.

[368] H. Liu, M. Li, B. Xiang, et al., “An Integrated “Engage & Evasion” Approach for Mononuclear Phagocyte System Escape and Efficient Extracellular Vesicle Therapy,” Journal of Nanobiotechnology 22, no. 1 (2024): 770.

[369] M. Cheng, D. de la Cruz, A. V. Crain, et al., “Probing Aspects of Extracellular Vesicle Associated AAV Allows Increased Vector Yield and Insight into Its Transduction and Immune-evasive Properties,” Molecular Therapy Methods & Clinical Development 33, no. 1 (2025): 101407.

[370] I. Ros-Gañán, M. Hommel, and L. Trigueros-Motos, “Optimising the IgG-degrading Enzyme Treatment Regimen for Enhanced Adeno-associated Virus Transduction in the Presence of Neutralising Antibodies,” Clinical & Translational Immunology 11, no. 2 (2022): e1375.

[371] S. El Andaloussi, I. Mäger, X. O. Breakefield, and M. J. Wood, “Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities,” Nature Reviews Drug Discovery 12, no. 5 (2013): 347–357.

[372] A. Bobrie, M. Colombo, G. Raposo, and C. Théry, “Exosome Secretion: Molecular Mechanisms and Roles in Immune Responses,” Traffic 12, no. 12 (2011): 1659–1668.

[373] A. Akinc, W. Querbes, S. De, et al., “Targeted Delivery of RNAi Therapeutics with Endogenous and Exogenous Ligand-Based Mechanisms,” Molecular Therapy 18, no. 7 (2010): 1357–1364.

[374] F. Sebastiani and M. Lerche, “Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-containing Lipid Nanoparticles,” ACS Nano 15, no. 4 (2021): 6709–6722.

[375] Y. T. Sato, K. Umezaki, S. Sawada, et al., “Engineering Hybrid Exosomes by Membrane Fusion with Liposomes,” Scientific Reports 6, no. 1 (2016): 21933.

[376] Y. Lin, J. Wu, W. Gu, et al., “Exosome–liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs,” Advanced Science 5, no. 4 (2018): 1700611.

[377] B. Gharehchelou, M. Mehrarya, Y. Sefidbakht, et al., “Mesenchymal Stem Cell-derived Exosome and Liposome Hybrids as Transfection Nanocarriers of Cas9-GFP Plasmid to HEK293T Cells,” PLoS One 20, no. 1 (2025): e0315168.

[378] Z. Li, X. Zhou, M. Wei, et al., “In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR/dCas9,” Nano Letters 19, no. 1 (2018): 19–28.

[379] E. Trofimenko, G. Grasso, M. Heulot, et al., “Genetic, Cellular, and Structural Characterization of the Membrane Potential-dependent Cell-penetrating Peptide Translocation Pore,” Elife 10 (2021): e69832.

[380] J. V. V. Arafiles, J. Franke, L. Franz, J. Gomez-Gonzalez, K. Kemnitz-Hassanin, and C. P. Hackenberger, “Cell-surface-retained Peptide Additives for the Cytosolic Delivery of Functional Proteins,” Journal of the American Chemical Society 145, no. 45 (2023): 24535–24548.

[381] Z. Tan, Y. Jiang, M. S. Ganewatta, et al., “Block Polymer Micelles Enable CRISPR/Cas9 ribonucleoprotein Delivery: Physicochemical Properties Affect Packaging Mechanisms and Gene Editing Efficiency,” Macromolecules 52, no. 21 (2019): 8197–8206.

[382] J. Guo, T. Wan, B. Li, et al., “Rational Design of Poly (disulfide) s as a Universal Platform for Delivery of CRISPR-Cas9 Machineries toward Therapeutic Genome Editing,” ACS Central Science 7, no. 6 (2021): 990–1000.

[383] K. Lee, M. Conboy, H. M. Park, et al., “Nanoparticle Delivery of Cas9 ribonucleoprotein and Donor DNA in Vivo Induces Homology-directed DNA Repair,” Nature Biomedical Engineering 1, no. 11 (2017): 889–901.

[384] L. C. Dk, L. Kadunc, M. M. Keber, I. H. Bratkovic, R. Romih, and R. Jerala, “Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation,” ACS Synthetic Biology 7, no. 12 (2018): 2715–2725.

[385] J. Park, K. Y. Rhoo, Y. Kim, Y.-S. Kim, and S. R. Paik, “Cell-Division-Independent Rapid Expression of DNA Delivered with α-Synuclein–Gold Nanoparticle Conjugates,” ACS Applied Materials & Interfaces 17, no. 10 (2025): 14846–14858.

[386] R. G. Cuomo, Z. Zhang, K. Yamada, et al., “Expression and Purification of Cell-penetrating Cas9 and Cas12a Enzymes for Peptide-assisted Genome Editing,” Methods in Enzymology 705 (2024): 25–49, Elsevier.

[387] İ. I. Gümüşoğlu, M. Maloverjan, L. Porosk, and M. Pooga, “Supplementation with Ions Enhances the Efficiency of Nucleic Acid Delivery with Cell-penetrating Peptides,” Biochimica et Biophysica Acta (BBA)-General Subjects 1868, no. 12 (2024): 130719.

[388] M. Auger, L. Sorroza-Martinez, N. Brahiti, et al., “Enhancing Peptide and PMO Delivery to Mouse Airway Epithelia by Chemical Conjugation with the Amphiphilic Peptide S10,” Molecular Therapy Nucleic Acids 35, no. 3 (2024): 102290.

[389] S. Ma, Y. Li, F. Liu, et al., “Hierarchical-unlocking Virus-esque NanoCRISPR Precisely Disrupts Autocrine and Paracrine Pathway of VEGF for Tumor Inhibition and Antiangiogenesis,” Journal of Controlled Release 366 (2024): 505–518.

[390] M. Luo, J. Ma, X. Cheng, et al., “Genome Editing in Ferret Airway Epithelia Mediated by CRISPR/Nucleases Delivered with Amphiphilic Shuttle Peptides,” Human Gene Therapy 34, no. 15-16 (2023): 705–718.

[391] R. Navaridas, M. Vidal-Sabanés, A. Ruiz-Mitjana, et al., “In Vivo Intra-Uterine Delivery of TAT-Fused Cre Recombinase and CRISPR/Cas9 Editing System in Mice Unveil Histopathology of Pten/p53-Deficient Endometrial Cancers,” Advanced Science 10, no. 32 (2023): e2303134.

[392] K.-H. Shen, T.-H. Chiu, K.-C. Teng, J. Yu, and Y.-C. Yeh, “Fabrication of Triple-crosslinked Gelatin/Alginate Hydrogels for Controlled Release Applications,” International Journal of Biological Macromolecules 250 (2023): 126133.

[393] P. Yang, X. Yao, X. Tian, et al., “Supramolecular Peptide Hydrogel Epitope Vaccine Functionalized with CAR-T Cells for the Treatment of Solid Tumors,” Materials Today Bio 31 (2025): 101517.

[394] C. Zhong, S. He, Y. Huang, et al., “Scaffold-Based Non-viral CRISPR Delivery Platform for Efficient and Prolonged Gene Activation to Accelerate Tissue Regeneration,” Acta Biomaterialia 173 (2024): 283–297.

[395] W. H. Chooi, J. S. Chin, and S. Y. Chew, “Scaffold-Based Delivery of CRISPR/Cas9 Ribonucleoproteins for Genome Editing,” Methods in Molecular Biology (Clifton, NJ) 2211 (2020): 183–191.

[396] K. Zhang, W. H. Chooi, S. Liu, et al., “Localized Delivery of CRISPR/dCas9 via Layer-by-layer Self-assembling Peptide Coating on Nanofibers for Neural Tissue Engineering,” Biomaterials 256 (2020): 120225.

[397] Z. W. Tay, P. Chandrasekharan, A. Chiu-Lam, et al., “Magnetic Particle Imaging-guided Heating in Vivo Using Gradient Fields for Arbitrary Localization of Magnetic Hyperthermia Therapy,” ACS Nano 12, no. 4 (2018): 3699–3713.

[398] M. Mohammadi Ghanbarlou, S. Abdoli, and H. Omid, “Delivery of dCas9 Activator System Using Magnetic Nanoparticles Technology as a Vector Delivery Method for human Skin Fibroblast,” Magnetochemistry 9, no. 3 (2023): 71.

[399] H. Park, D. Kim, B. Cho, et al., “In Vivo Therapeutic Genome Editing via CRISPR/Cas9 Magnetoplexes for Myocardial Infarction,” Biomaterials 281 (2022): 121327.

[400] R. Liu, J. Yang, J. Yao, et al., “Optogenetic Control of RNA Function and Metabolism Using Engineered Light-switchable RNA-binding Proteins,” Nature Biotechnology 40, no. 5 (2022): 779–786.

[401] A. Hasanzadeh, H. Noori, A. Jahandideh, et al., “Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing,” ACS Applied Bio Materials 5, no. 2 (2022): 413–437.

[402] C. S. Lee, E. S. Bishop, R. Zhang, et al., “Adenovirus-mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine,” Genes & Diseases 4, no. 2 (2017): 43–63.

[403] A. Li, C. M. Lee, A. E. Hurley, et al., “A Self-deleting AAV-CRISPR System for in Vivo Genome Editing,” Molecular Therapy Methods & Clinical Development 12 (2019): 111–122.

[404] D. Yin, S. Ling, D. Wang, et al., “Targeting herpes Simplex Virus with CRISPR–Cas9 Cures Herpetic Stromal Keratitis in Mice,” Nature Biotechnology 39, no. 5 (2021): 567–577.

[405] D. Y. Kim, J. M. Lee, S. B. Moon, et al., “Efficient CRISPR Editing with a Hypercompact Cas12f1 and Engineered Guide RNAs Delivered by Adeno-associated Virus,” Nature Biotechnology 40, no. 1 (2022): 94–102.

[406] D. Wang, S. Li, D. J. Gessler, et al., “A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-directed and Peripheral Tissue-detargeted Gene Delivery in Neonates,” Molecular Therapy Methods & Clinical Development 9 (2018): 234–246.

[407] T. J. Gonzalez, K. E. Simon, L. O. Blondel, et al., “Cross-species Evolution of a Highly Potent AAV Variant for Therapeutic Gene Transfer and Genome Editing,” Nature Communications 13, no. 1 (2022): 5947.

[408] C. Leborgne, E. Barbon, J. M. Alexander, et al., “IgG-cleaving Endopeptidase Enables in Vivo Gene Therapy in the Presence of Anti-AAV Neutralizing Antibodies,” Nature Medicine 26, no. 7 (2020): 1096–1101.

[409] J. D. Finn, A. R. Smith, M. C. Patel, et al., “A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent in Vivo Genome Editing,” Cell Reports 22, no. 9 (2018): 2227–2235.

[410] G. Liu, K. Yin, Q. Zhang, C. Gao, and J.-L. Qiu, “Modulating Chromatin Accessibility by Transactivation and Targeting Proximal dsgRNAs Enhances Cas9 Editing Efficiency in Vivo,” Genome Biology 20, no. 1 (2019): 145.

[411] R. Nagamura, T. Kujirai, J. Kato, et al., “Structural Insights into How Cas9 Targets Nucleosomes,” Nature Communications 15, no. 1 (2024): 10744.

[412] M. Jin, J. Lin, H. Li, et al., “Correction of human Nonsense Mutation via Adenine Base Editing for Duchenne Muscular Dystrophy Treatment in Mouse,” Molecular Therapy Nucleic Acids 35, no. 2 (2024): 102165.

[413] Q. Cheng, T. Wei, Y. Jia, et al., “Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I,” Advanced Materials 30, no. 52 (2018): e1805308.

[414] N. Meng and D. Grimm, “Membrane-destabilizing Ionizable Phospholipids: Novel Components for Organ-selective mRNA Delivery and CRISPR–Cas Gene Editing,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 206.

[415] X. Zhu, G. Huang, C. Zeng, et al., “Structure of the Cytoplasmic Ring of the Xenopus laevis Nuclear Pore Complex,” Science 376, no. 6598 (2022): eabl8280.

[416] X. Li, D. Wang, Z. Cui, et al., “HIV-1 Viral Cores Enter the Nucleus Collectively through the Nuclear Endocytosis-like Pathway,” Science China Life Sciences 64, no. 1 (2021): 66–76.

[417] X. Guo and L. Huang, “Recent Advances in Nonviral Vectors for Gene Delivery,” Accounts of Chemical Research 45, no. 7 (2012): 971–979.

[418] F. Campbell, F. L. Bos, S. Sieber, et al., “Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-dependent Nanoparticle Uptake,” ACS Nano 12, no. 3 (2018): 2138–2150.

[419] L. N. Kasiewicz, S. Biswas, A. Beach, et al., “GalNAc-Lipid Nanoparticles Enable Non-LDLR Dependent Hepatic Delivery of a CRISPR Base Editing Therapy,” Nature Communications 14, no. 1 (2023): 2776.

[420] J. G. Rurik, I. Tombácz, A. Yadegari, et al., “CAR T Cells Produced in Vivo to Treat Cardiac Injury,” Science 375, no. 6576 (2022): 91–96.

[421] J. Bader, P. Rüedi, V. Mantella, et al., “Loading of Extracellular Vesicles With Nucleic Acids via Hybridization With Non-Lamellar Liquid Crystalline Lipid Nanoparticles,” Advanced Science 12, no. 8 (2025): e2404860.

[422] R. Cruz-Samperio, C. L. Hicks, A. Scott, et al., “Modular Bioorthogonal Lipid Nanoparticle Modification Platforms for Cardiac Homing,” Journal of the American Chemical Society 145, no. 41 (2023): 22659–22670.

[423] T. Chang, Y. Zheng, M. Jiang, et al., “Peptide Codes for Organ-selective mRNA Delivery,” Nature Materials 25, no. 1 (2026): 146–159.

[424] S. M. Salabarria, M. Corti, K. E. Coleman, et al., “Thrombotic Microangiopathy Following Systemic AAV Administration Is Dependent on Anti-capsid Antibodies,” The Journal of Clinical Investigation 134, no. 1 (2024): e173510.

[425] B. J. Byrne, R. J. Butterfield, P. B. Shieh, et al., “Complement Activation in a Phase Ib Study of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy,” Molecular Therapy 33, no. 9 (2025): 4226–4238.

[426] R. J. Butterfield, P. B. Shieh, H. Li, et al., “AAV Mini-dystrophin Gene Therapy for Duchenne Muscular Dystrophy: A Phase 1b Trial,” Nature Medicine 31, no. 8 (2025): 2712–2721.

[427] T. Smith, “Newly Engineered IgM and IgG Cleaving Enzymes for AAV Gene Therapy (ASGCT abstract 210),” Molecular Therapy 31 (2023): S1–794.

[428] M. Muhuri, Y. Maeda, H. Ma, et al., “Overcoming Innate Immune Barriers That Impede AAV Gene Therapy Vectors,” The Journal of Clinical Investigation 131, no. 1 (2021): e143780.

[429] Q. Liu, W. Huang, H. Zhang, et al., “Neutralizing Antibodies against AAV2, AAV5 and AAV8 in Healthy and HIV-1-infected Subjects in China: Implications for Gene Therapy Using AAV Vectors,” Gene Therapy 21, no. 8 (2014): 732–738.

[430] Y. Zhu, J. Antony, S. Liu, et al., “CD8+ lymphocyte-mediated Injury of Dorsal Root Ganglion Neurons during Lentivirus Infection: CD154-dependent Cell Contact Neurotoxicity,” Journal of Neuroscience 26, no. 13 (2006): 3396–3403.

[431] M. Koga, M. Fujiwara, S. Ariga, et al., “CD8+ T-lymphocytes Infiltrate the Myocardium in Fulminant herpes Virus Myocarditis,” Pediatric Pathology & Molecular Medicine 20, no. 3 (2001): 189–195.

[432] M. Muhuri, W. Zhan, Y. Maeda, et al., “Novel Combinatorial microRNA-binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction,” Frontiers in Immunology 12 (2021): 674242.

[433] J. Hordeaux, E. L. Buza, B. Jeffrey, et al., “MicroRNA-mediated Inhibition of Transgene Expression Reduces Dorsal Root Ganglion Toxicity by AAV Vectors in Primates,” Science Translational Medicine 12, no. 569 (2020): eaba9188.

[434] A. M. Moreno, N. Palmer, F. Alemán, et al., “Immune-Orthogonal Orthologues of AAV Capsids and of Cas9 Circumvent the Immune Response to the Administration of Gene Therapy,” Nature Biomedical Engineering 3, no. 10 (2019): 806–816.

[435] K. S. Hanlon, B. P. Kleinstiver, S. P. Garcia, et al., “High Levels of AAV Vector Integration into CRISPR-induced DNA Breaks,” Nature Communications 10, no. 1 (2019): 4439.

[436] D. M. McCarty, S. M. Young Jr, and R. J. Samulski, “Integration of Adeno-associated Virus (AAV) and Recombinant AAV Vectors,” Annual Review of Genetics 38, no. 1 (2004): 819–845.

[437] N. H. Staunstrup and J. G. Mikkelsen, “Integrase-defective Lentiviral Vectors-a Stage for Nonviral Integration Machineries,” Current Gene Therapy 11, no. 5 (2011): 350–362.

[438] J. B. Kwon, A. R. Ettyreddy, A. Vankara, et al., “In Vivo Gene Editing of Muscle Stem Cells with Adeno-associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy,” Molecular Therapy Methods & Clinical Development 19 (2020): 320–329.

[439] R. J. Chandler, M. S. Sands, and C. P. Venditti, “Recombinant Adeno-associated Viral Integration and Genotoxicity: Insights from Animal Models,” Human Gene Therapy 28, no. 4 (2017): 314–322.

[440] M. L. Maeder, M. Stefanidakis, C. J. Wilson, et al., “Development of a Gene-editing Approach to Restore Vision Loss in Leber Congenital Amaurosis Type 10,” Nature Medicine 25, no. 2 (2019): 229–233.

[441] S. J. Shepherd, X. Han, A. J. Mukalel, et al., “Throughput-scalable Manufacturing of SARS-CoV-2 mRNA Lipid Nanoparticle Vaccines,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 33 (2023): e2303567120.

[442] M. Balwani, E. Sardh, P. Ventura, et al., “Phase 3 Trial of RNAi Therapeutic givosiran for Acute Intermittent Porphyria,” New England Journal of Medicine 382, no. 24 (2020): 2289–2301.

[443] S. Liu, J. Li, S. Peraramelli, et al., “Systematic Comparison of rAAV Vectors Manufactured Using Large-scale Suspension Cultures of Sf9 and HEK293 Cells,” Molecular Therapy 32, no. 1 (2024): 74–83.

[444] W. Su, M. I. Patrício, M. R. Duffy, J. M. Krakowiak, L. W. Seymour, and R. Cawood, “Self-attenuating adenovirus Enables Production of Recombinant Adeno-associated Virus for High Manufacturing Yield without Contamination,” Nature Communications 13, no. 1 (2022): 1182.

[445] J.-Y. Huang, Y. Gao, L. Cutlar, et al., “Tailoring Highly Branched Poly (β-amino ester) s: A Synthetic Platform for Epidermal Gene Therapy,” Chemical Communications 51, no. 40 (2015): 8473–8476.

[446] L. Rotolo, D. Vanover, N. C. Bruno, et al., “Species-agnostic Polymeric Formulations for Inhalable Messenger RNA Delivery to the Lung,” Nature Materials 22, no. 3 (2023): 369–379.

[447] T. I. Cornu, C. Mussolino, and T. Cathomen, “Refining Strategies to Translate Genome Editing to the Clinic,” Nature Medicine 23, no. 4 (2017): 415–423.

[448] S. Rangarajan, L. Walsh, W. Lester, et al., “AAV5–factor VIII gene transfer in severe hemophilia A,” New England Journal of Medicine 377, no. 26 (2017): 2519–2530.

[449] A. R. Bass, S. Kimball, A. Jenkins, et al., “Elucidating the Immunogenic Mechanisms of Merck's Lipid Nanoparticle (LNP) Adjuvants,” The Journal of Immunology 208, no. Supplement_1 (2022): 50.

[450] N. Dejneka, A. Auricchio, A. Maguire, et al., “Pharmacologically Regulated Gene Expression in the Retina Following Transduction with Viral Vectors,” Gene Therapy 8, no. 6 (2001): 442–446.

[451] Z. J. Tickner and M. Farzan, “Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-associated Viral Vectors,” Pharmaceuticals 14, no. 06 (2021): 554.

[452] S. Merlin and A. Follenzi, “Transcriptional Targeting and microRNA Regulation of Lentiviral Vectors,” Molecular Therapy Methods & Clinical Development 12 (2019): 223–232.

[453] M. Davari, H. Ahmadieh, Z.-S. Soheili, S. Samiei, E. Ranaei, and M. R. Kanavi, “Construction of Recombinant AAV-Based Vectors Bearing miR-183 Cluster Genes,” Investigative Ophthalmology & Visual Science 55, no. 13 (2014): 3465–3465.

[454] T. Horie and K. Ono, “VERVE-101: A Promising CRISPR-Based Gene Editing Therapy That Reduces LDL-C and PCSK9 Levels in HeFH Patients,” European Heart Journal of Cardiovascular Pharmacotherapy 10, no. 2 (2024): 89–90.

[455] N. K. Paulk, K. Pekrun, E. Zhu, et al., “Bioengineered AAV Capsids with Combined High human Liver Transduction in Vivo and Unique Humoral Seroreactivity,” Molecular Therapy 26, no. 1 (2018): 289–303.

[456] B. Cetin, F. Erendor, Y. E. Eksi, A. D. Sanlioglu, and S. Sanlioglu, “Advancing CRISPR Genome Editing into Gene Therapy Clinical Trials: Progress and Future Prospects,” Expert Reviews in Molecular Medicine 27 (2025): e16.

[457] C. Simoni, E. Barbon, A. F. Muro, and A. Cantore, “In Vivo Liver Targeted Genome Editing as Therapeutic Approach: Progresses and Challenges,” Frontiers in Genome Editing 6 (2024): 1458037.

[458] A. J. Hooper, X. L. Tang, and J. R. Burnett, “VERVE-101, a CRISPR Base-editing Therapy Designed to Permanently Inactivate Hepatic PCSK9 and Reduce LDL-cholesterol,” Expert Opinion on Investigational Drugs 33, no. 8 (2024): 753–756.

[459] E. Rohde, R. Lee, A. M. Mazzola, et al., “Nonclinical Data Demonstrate Potent and Precise Inactivation of Liver PCSK9 in Vivo with the Clinical Stage GalNAc Base Editing Medicine, VERVE-102,” Atherosclerosis 407 (2025): 120333.

[460] O. G. Segurado, R. Jiang, and S. W. Pipe, “Challenges and Opportunities When Transitioning from in Vivo Gene Replacement to in Vivo CRISPR/Cas9 Therapies–a Spotlight on Hemophilia,” Expert Opinion on Biological Therapy 22, no. 9 (2022): 1091–1098.

[461] L. Wang, Y. Yang, C. A. Breton, et al., “CRISPR/Cas9-mediated in Vivo Gene Targeting Corrects Hemostasis in Newborn and Adult Factor IX–knockout Mice,” Blood, The Journal of the American Society of Hematology 133, no. 26 (2019): 2745–2752.

[462] H. Chen, M. Shi, A. Gilam, et al., “Hemophilia A Ameliorated in Mice by CRISPR-Based in Vivo Genome Editing of human Factor VIII,” Scientific Reports 9, no. 1 (2019): 16838.

[463] G. Liuzzo and C. Patrono, “First in Man: Gene Editing for the Treatment of Transthyretin Amyloidosis,” European Heart Journal 42, no. 36 (2021): 3597–3598.

[464] R. Han, “First in Vivo Base-editing Trial Shows Promise,” Molecular Therapy 32, no. 1 (2024): 1–2.

[465] J. Wang, W. Zheng, S. Zheng, et al., “Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 Lowers Blood Lipids with Long-lasting and Potent Efficacy in Mice and Monkeys,” Molecular Therapy Nucleic Acids 31 (2023): 68–77.

[466] P. M. Mannucci, “Hemophilia Treatment Innovation: 50 Years of Progress and More to Come,” Journal of Thrombosis and Haemostasis 21, no. 3 (2023): 403–412.

[467] C. D. Thornburg, “Etranacogene dezaparvovec for Hemophilia B Gene Therapy,” Therapeutic Advances in Rare Disease 2 (2021): 26330040211058896.

[468] M. C. Ozelo, J. Mahlangu, K. J. Pasi, et al., “Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A,” New England Journal of Medicine 386, no. 11 (2022): 1013–1025.

[469] T. R. Flotte, “Size Does Matter: Overcoming the Adeno-associated Virus Packaging Limit,” Respiratory Research 1, no. 1 (2000): 16–18.

[470] Y. Yang, L. Wang, P. Bell, et al., “A Dual AAV System Enables the Cas9-mediated Correction of a Metabolic Liver Disease in Newborn Mice,” Nature Biotechnology 34, no. 3 (2016): 334–338.

[471] A. Philippidis, “CASGEVY makes history as FDA approves first CRISPR/Cas9 genome edited therapy,” Human Gene Therapy 35, no. 1-2 (2024): 1–4.

[472] E. Y. Adashi, P. A. Gruppuso, and I. G. Cohen, “CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era,” The American Journal of Medicine 137, no. 5 (2024): 390–392.

[473] A. Lattanzi, J. Camarena, P. Lahiri, et al., “Development of β-globin Gene Correction in human Hematopoietic Stem Cells as a Potential Durable Treatment for Sickle Cell Disease,” Science Translational Medicine 13, no. 598 (2021): eabf2444.

[474] J. Zeng, Y. Wu, C. Ren, et al., “Therapeutic Base Editing of human Hematopoietic Stem Cells,” Nature Medicine 26, no. 4 (2020): 535–541.

[475] K. A. Everette, G. A. Newby, R. M. Levine, et al., “Ex Vivo Prime Editing of Patient Haematopoietic Stem Cells Rescues Sickle-cell Disease Phenotypes after Engraftment in Mice,” Nature Biomedical Engineering 7, no. 5 (2023): 616–628.

[476] R. Renella, A. Perlov, C. E. Harris, et al., “Hematopoietic SIN Lentiviral Micro RNA-mediated Silencing of BCL11A: Pre-clinical Evidence for a Sickle Cell Disease Gene-therapy Trial,” Blood 120, no. 21 (2012): 753.

[477] J. Brault, T. Liu, S. Liu, et al., “CRISPR-Cas9-AAV versus Lentivector Transduction for Genome Modification of X-linked Severe Combined Immunodeficiency Hematopoietic Stem Cells,” Frontiers in Immunology 13 (2023): 1067417.

[478] S. S. De Ravin, A. Reik, P.-Q. Liu, et al., “Targeted Gene Addition in human CD34+ Hematopoietic Cells for Correction of X-linked Chronic Granulomatous Disease,” Nature Biotechnology 34, no. 4 (2016): 424–429.

[479] K. L. Hung, I. Meitlis, M. Hale, et al., “Engineering Protein-secreting Plasma Cells by Homology-directed Repair in Primary human B Cells,” Molecular Therapy 26, no. 2 (2018): 456–467.

[480] S. Li, L. Holguin, and J. C. Burnett, “CRISPR-Cas9-mediated Gene Disruption of HIV-1 co-receptors Confers Broad Resistance to Infection in human T Cells and Humanized Mice,” Molecular Therapy Methods & Clinical Development 24 (2022): 321–331.

[481] S. Demirci, M. B. Khan, G. Hinojosa, et al., “Ex Vivo Culture Resting Time Impacts Transplantation Outcomes of Genome-edited human Hematopoietic Stem and Progenitor Cells in Xenograft Mouse Models,” Cytotherapy 26, no. 6 (2024): 641–648.

[482] R. El-Kharrag, K. E. Berckmueller, R. Madhu, et al., “Efficient Polymer Nanoparticle-mediated Delivery of Gene Editing Reagents into human Hematopoietic Stem and Progenitor Cells,” Molecular Therapy 30, no. 6 (2022): 2186–2198.

[483] J. Yen, M. Fiorino, Y. Liu, et al., “TRIAMF: A New Method for Delivery of Cas9 ribonucleoprotein Complex to human Hematopoietic Stem Cells,” Scientific Reports 8, no. 1 (2018): 16304.

[484] O. Quintana-Bustamante, S. Fañanas-Baquero, I. Orman, et al., “Gene Editing of PKLR Gene in human Hematopoietic Progenitors through 5‘and 3’UTR Modified TALEN mRNA,” PLoS One 14, no. 10 (2019): e0223775.

[485] D. Duan, “Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy,” Molecular Therapy 26, no. 10 (2018): 2337–2356.

[486] S.-K. Zhou, J.-T. Luo, Y.-F. Chen, et al., “Muscle-specific Gene Editing Therapy via Mammalian Fusogen-directed Virus-like Particles,” Nature Communications 16, no. 1 (2025): 9145.

[487] A. Kowala, J. Boot, J. Meng, et al., “Engineered human Myogenic Cells in Hydrogels Generate Innervated Vascularized Myofibers within Dystrophic Mouse Muscle on Long-term Engraftment,” Cell Reports Medicine 6, no. 3 (2025): 102019.

[488] M. Chen, Y. Liu, Q. Liu, et al., “Nanoengineered Cargo with Targeted in Vivo Foxo3 Gene Editing Modulated Mitophagy of Chondrocytes to Alleviate Osteoarthritis,” Acta Pharmaceutica Sinica B 15, no. 1 (2025): 571–591.

[489] M. Chen, Y. Lu, Y. Liu, et al., “Injectable Microgels with Hybrid Exosomes of Chondrocyte-targeted FGF18 Gene-editing and Self-renewable Lubrication for Osteoarthritis Therapy,” Advanced Materials 36, no. 16 (2024): e2312559.

[490] A. Bonato, P. Fisch, S. Ponta, et al., “Engineering inflammation-resistant cartilage: Bridging gene therapy and tissue engineering,” Advanced Healthcare Materials 12, no. 17 (2023): e2202271.

[491] L. H. Cobb, J. Park, E. A. Swanson, et al., “CRISPR-Cas9 Modified Bacteriophage for Treatment of Staphylococcus aureus Induced Osteomyelitis and Soft Tissue Infection,” PLoS One 14, no. 11 (2019): e0220421.

[492] Y. Yao, J. Wang, Y. Liu, et al., “Variants of the Adeno-associated Virus Serotype 9 with Enhanced Penetration of the Blood–brain Barrier in Rodents and Primates,” Nature Biomedical Engineering 6, no. 11 (2022): 1257–1271.

[493] K. D. Foust, E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan, and B. K. Kaspar, “Intravascular AAV9 Preferentially Targets Neonatal Neurons and Adult Astrocytes,” Nature Biotechnology 27, no. 1 (2009): 59–65.

[494] S. R. Choudhury, E. Hudry, C. A. Maguire, M. Sena-Esteves, X. O. Breakefield, and P. Grandi, “Viral Vectors for Therapy of Neurologic Diseases,” Neuropharmacology 120 (2017): 63–80.

[495] T. Kurano, T. Kanazawa, A. Ooba, et al., “Nose-to-brain/Spinal Cord Delivery Kinetics of Liposomes with Different Surface Properties,” Journal of Controlled Release 344 (2022): 225–234.

[496] K. Gao, H. Han, M. G. Cranick, et al., “Widespread Gene Editing in the Brain via in Utero Delivery of mRNA Using Acid-degradable Lipid Nanoparticles,” ACS Nano 18, no. 44 (2024): 30293–30306.

[497] J. Li, J. Tuma, H. Han, et al., “The Coiled-coil Forming Peptide (KVSALKE) 5 Is a Cell Penetrating Peptide That Enhances the Intracellular Delivery of Proteins,” Advanced Healthcare Materials 11, no. 9 (2022): e2102118.

[498] M. Cui, Q. Su, M. Yip, et al., “The AAV2. 7m8 Capsid Packages a Higher Degree of Heterogeneous Vector Genomes than AAV2,” Gene Therapy 31, no. 9 (2024): 489–498.

[499] X. Pan, P. Huang, S. S. Ali, et al., “Extracellular Vesicle–mediated Gene Editing for the Treatment of Nonsyndromic Progressive Hearing Loss in Adult Mice,” Science Translational Medicine 17, no. 824 (2025): eadn3993.

[500] G.-X. Ruan, E. Barry, D. Yu, M. Lukason, S. H. Cheng, and A. Scaria, “CRISPR/Cas9-mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10,” Molecular Therapy 25, no. 2 (2017): 331–341.

[501] K. T. McCullough, S. L. Boye, D. Fajardo, et al., “Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque,” Human Gene Therapy 30, no. 5 (2019): 571–589.

[502] D. H. Jo, H.-K. Jang, C. S. Cho, et al., “Visual Function Restoration in a Mouse Model of Leber Congenital Amaurosis via Therapeutic Base Editing,” Molecular Therapy Nucleic Acids 31 (2023): 16–27.

[503] D. Baraniak and J. Boryski, “Triazole-modified Nucleic Acids for the Application in Bioorganic and Medicinal Chemistry,” Biomedicines 9, no. 6 (2021): 628.

[504] M. Sioud, “Single-stranded Small Interfering RNA Are More Immunostimulatory than Their Double-stranded Counterparts: A central Role for 2′-hydroxyl Uridines in Immune Responses,” European Journal of Immunology 36, no. 5 (2006): 1222–1230.

[505] H. A. Dad, T.-W. Gu, A.-Q. Zhu, L.-Q. Huang, and L.-H. Peng, “Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms,” Molecular Therapy 29, no. 1 (2021): 13–31.

[506] R. T. Walton, K. A. Christie, M. N. Whittaker, and B. P. Kleinstiver, “Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants,” Science 368, no. 6488 (2020): 290–296.

[507] Y. Wang, Y.-L. Feng, Q. Liu, et al., “TREX2 enables Efficient Genome Disruption Mediated by Paired CRISPR-Cas9 Nickases That Generate 3′-overhanging Ends,” Molecular Therapy Nucleic Acids 34 (2023): 102072.

[508] J. Yu, J. Shin, J. Yu, J. Kim, D. Yu, and W. D. Heo, “Programmable RNA Base Editing with Photoactivatable CRISPR-Cas13,” Nature Communications 15, no. 1 (2024): 673.

[509] C. Sago, E. Campbell, B. Lutz, et al., “Screening of Chemically Distinct Lipid Nanoparticles in Vivo Using DNA Barcoding Technology towards Effectively Delivering Messenger RNA to Hematopoietic Stem and Progenitor Cells,” Blood 138 (2021): 2931.

[510] M. T. Yarnall, E. I. Ioannidi, C. Schmitt-Ulms, et al., “Drag-and-drop Genome Insertion of Large Sequences without Double-strand DNA Cleavage Using CRISPR-directed Integrases,” Nature Biotechnology 41, no. 4 (2023): 500–512.

[511] C. D. Sago, M. P. Lokugamage, K. Paunovska, et al., “High-throughput in Vivo Screen of Functional mRNA Delivery Identifies Nanoparticles for Endothelial Cell Gene Editing,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 42 (2018): E9944–E9952.

[512] H. Ni, M. Z. Hatit, K. Zhao, et al., “Piperazine-derived Lipid Nanoparticles Deliver mRNA to Immune Cells in Vivo,” Nature Communications 13, no. 1 (2022): 4766.

[513] M. Z. Hatit, M. P. Lokugamage, C. N. Dobrowolski, et al., “Species-dependent in Vivo mRNA Delivery and Cellular Responses to Nanoparticles,” Nature Nanotechnology 17, no. 3 (2022): 310–318.

[514] M.-R. Wu, L. Nissim, D. Stupp, et al., “A High-throughput Screening and Computation Platform for Identifying Synthetic Promoters with Enhanced Cell-state Specificity (SPECS),” Nature Communications 10, no. 1 (2019): 2880.

[515] L. Yang, F. Ma, F. Liu, J. Chen, X. Zhao, and Q. Xu, “Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles in Vitro and in Vivo,” Molecular Therapy Nucleic Acids 19 (2020): 1357–1367.

[516] A. Maddalena, F. Dell'Aquila, P. Giovannelli, et al., “High-throughput Screening Identifies Kinase Inhibitors That Increase Dual Adeno-associated Viral Vector Transduction in Vitro and in Mouse Retina,” Human Gene Therapy 29, no. 8 (2018): 886–901.

[517] L. Palmieri, M. Ferrand, I. Richard, and S. Albini, “In Silico Structural Prediction for the Generation of Novel Performant Midi-dystrophins Based on Intein-mediated Dual AAV Approach,” International Journal of Molecular Sciences 25, no. 19 (2024): 10444.

[518] S. Da, A. J. Sanchez, C. Dobrowolski, A. Cristian, et al., “Universal Barcoding Predicts in Vivo ApoE-independent Lipid Nanoparticle Delivery,” Nano Letters 22, no. 12 (2022): 4822–4830.

[519] Z. Ban, P. Yuan, F. Yu, T. Peng, Q. Zhou, and X. Hu, “Machine Learning Predicts the Functional Composition of the Protein Corona and the Cellular Recognition of Nanoparticles,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 19 (2020): 10492–10499.

[520] Y. Zhang, C. Sun, C. Wang, K. E. Jankovic, and Y. Dong, “Lipids and Lipid Derivatives for RNA Delivery,” Chemical Reviews 121, no. 20 (2021): 12181–12277.

[521] S. Vafai, V. Karsten, C. Jensen, et al., “Design of Heart-2: A Phase 1b Clinical Trial of VERVE-102, an in Vivo Base Editing Medicine Delivered by a GalNAc-LNP and Targeting PCSK9 to Durably Lower LDL Cholesterol,” Circulation 150, no. Suppl_1 (2024): A4139206.

[522] A. Watanabe, M. Nakajima, T. Kasuya, et al., “Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B,” The Journal of Pharmacology and Experimental Therapeutics 357, no. 2 (2016): 320–330.

[523] M. M. Zwartkruis and E. J. Groen, “Promoting Expression in Gene Therapy: More Is Not Always Better,” EMBO Molecular Medicine 16, no. 4 (2024): 672–674.

[524] S.-H. Hsu, B. Wang, J. Kota, et al., “Essential Metabolic, Anti-inflammatory, and Anti-tumorigenic Functions of miR-122 in Liver,” The Journal of Clinical Investigation 122, no. 8 (2012): 2871–2883.

[525] N. Bamidele, H. Zhang, X. Dong, et al., “Domain-inlaid Nme2Cas9 Adenine Base Editors with Improved Activity and Targeting Scope,” Nature Communications 15, no. 1 (2024): 1458.

[526] D. Ma, S. Peng, W. Huang, Z. Cai, and Z. Xie, “Rational Design of Mini-Cas9 for Transcriptional Activation,” ACS Synthetic Biology 7, no. 4 (2018): 978–985.

[527] R. Lee, A. M. Mazzola, M. Braun, et al., “VERVE-101—An Investigational Single-Course Gene Editing Medicine Targeting PCSK9—Durably and Potently Lowers PCSK9 and LDL-C Concentrations in Non-Human Primates,” Circulation 146, no. Suppl_1 (2022): A11274.

[528] A. Hollar, H. Bursey, and H. Jabbari, “Pseudoknots in RNA Structure Prediction,” Current Protocols 3, no. 2 (2023): e661.

[529] L. Zhang, X.-H. Liang, and C. L. De Hoyos, “The Combination of Mesyl-phosphoramidate Inter-nucleotide Linkages and 2′-O-Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs,” Nucleic Acid Therapeutics 32, no. 5 (2022): 401–411.

[530] Z. Chen, K. Kelly, H. Cheng, et al., “In Vivo Prime Editing by Lipid Nanoparticle co-delivery of Chemically Modified pegRNA and Prime Editor mRNA,” GEN Biotechnology 2, no. 6 (2023): 490–502.

[531] L. Yang, H. Li, A. Luo, et al., “Macrophage Membrane-camouflaged pH-sensitive Nanoparticles for Targeted Therapy of Oral Squamous Cell Carcinoma,” Journal of Nanobiotechnology 22, no. 1 (2024): 168.

[532] D. B. Cox, J. S. Gootenberg, O. O. Abudayyeh, et al., “RNA Editing with CRISPR-Cas13,” Science 358, no. 6366 (2017): 1019–1027.

[533] A. K. Patel, J. C. Kaczmarek, S. Bose, et al., “Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium,” Advanced Materials 31, no. 8 (2019): e1805116.

[534] R. Calcedo, L. H. Vandenberghe, G. Gao, J. Lin, and J. M. Wilson, “Worldwide Epidemiology of Neutralizing Antibodies to Adeno-associated Viruses,” The Journal of Infectious Diseases 199, no. 3 (2009): 381–390.

[535] L. A. George, S. K. Sullivan, A. Giermasz, et al., “Hemophilia B Gene Therapy with a High-specific-activity Factor IX Variant,” New England Journal of Medicine 377, no. 23 (2017): 2215–2227.

[536] A. Majowicz, D. Salas, N. Zabaleta, et al., “Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1,” Molecular Therapy 25, no. 8 (2017): 1831–1842.

[537] X. Zhou, M. Jaiswal, J. Shi, et al., “Efficient Enzymatic Glycan Engineering of Extracellular Vesicles Using Nanomaterial-interfaced Microfluidics,” ACS Applied Materials & Interfaces 17, no. 1 (2024): 2689–2700.

[538] Y. Tian, H. Lv, Y. Ju, J. Hao, and J. Cui, “Zwitterionic Poly (ethylene glycol) Nanoparticles Minimize Protein Adsorption and Immunogenicity for Improved Biological Fate,” ACS Applied Materials & Interfaces 17, no. 4 (2025): 6125–6133.

[539] T. K. Kishimoto, M. Fournier, A. Michaud, et al., “Rapamycin Nanoparticles Increase the Therapeutic Window of Engineered Interleukin-2 and Drive Expansion of Antigen-specific Regulatory T Cells for Protection against Autoimmune Disease,” Journal of Autoimmunity 140 (2023): 103125.

[540] T. Karamanidou and A. Tsouknidas, “Plant-derived Extracellular Vesicles as Therapeutic Nanocarriers,” International Journal of Molecular Sciences 23, no. 1 (2021): 191.

[541] M. Corti, M. Elder, D. Falk, et al., “B-cell Depletion Is Protective against Anti-AAV Capsid Immune Response: A human Subject Case Study,” Molecular Therapy Methods & Clinical Development 1 (2014): 14033.

[542] A. Kistner, J. A. Chichester, L. Wang, et al., “Prednisolone and Rapamycin Reduce the Plasma Cell Gene Signature and May Improve AAV Gene Therapy in Cynomolgus Macaques,” Gene Therapy 31, no. 3 (2024): 128–143.

[543] Z. C. Elmore, D. K. Oh, K. E. Simon, M. M. Fanous, and A. Asokan, “Rescuing AAV Gene Transfer from Neutralizing Antibodies with an IgG-degrading Enzyme,” JCI Insight 5, no. 19 (2020): e139881.

[544] N. Chaudhary, L. N. Kasiewicz, A. N. Newby, et al., “Amine Headgroups in Ionizable Lipids Drive Immune Responses to Lipid Nanoparticles by Binding to the Receptors TLR4 and CD1d,” Nature Biomedical Engineering 8, no. 11 (2024): 1483–1498.

[545] S. Dixon, X. Kang, and D. Quan, “Practical Guidance for the Use of patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-mediated Amyloidosis,” Therapeutics and Clinical Risk Management 19 (2023): 973–981.

[546] S. Demirci, A. Leonard, K. Essawi, and J. F. Tisdale, “CRISPR-Cas9 to Induce Fetal Hemoglobin for the Treatment of Sickle Cell Disease,” Molecular Therapy Methods & Clinical Development 23 (2021): 276–285.

[547] T. Weeden, T. Picariello, B. Quinn, et al., “FORCE Platform Overcomes Barriers of Oligonucleotide Delivery to Muscle and Corrects Myotonic Dystrophy Features in Preclinical Models,” Communications Medicine 5, no. 1 (2025): 22.

[548] U. Etxaniz, I. Marks, T. Albin, et al., “AOC 1044 Induces Exon 44 Skipping and Restores Dystrophin Protein in Preclinical Models of Duchenne Muscular Dystrophy,” Nucleic Acids Research 53, no. 6 (2025): gkaf241.

[549] S. Yoon, X. Wu, B. Armstrong, N. Habib, and J. J. Rossi, “An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma,” Molecular Therapy Nucleic Acids 14 (2019): 131–141.

[550] X. Yan, Q. Pan, H. Xin, Y. Chen, and Y. Ping, “Genome-editing Prodrug: Targeted Delivery and Conditional Stabilization of CRISPR-Cas9 for Precision Therapy of Inflammatory Disease,” Science Advances 7, no. 50 (2021): eabj0624.

[551] B. S. Lewis, “First-in-human Trial of PCSK9 Gene Editing Therapy for Lowering Cholesterol: A New Frontier in Cardiovascular Pharmacotherapy? News from AHA,” European Heart Journal of Cardiovascular Pharmacotherapy 10, no. 2 (2024): 87–88.

[552] L. W. Koblan, M. R. Erdos, C. Wilson, et al., “In Vivo Base Editing Rescues Hutchinson–Gilford Progeria Syndrome in Mice,” Nature 589, no. 7843 (2021): 608–614.

[553] F. Chemello, A. Chai, H. Li, et al., “Precise Correction of Duchenne Muscular Dystrophy Exon Deletion Mutations by Base and Prime Editing,” Science Advances 7, no. 18 (2021): eabg4910.

[554] B. Dhungel, C. A. Ramlogan-Steel, and J. C. Steel, “Synergistic and Independent Action of Endogenous microRNAs 122a and 199a for Post-transcriptional Liver Detargeting of Gene Vectors,” Scientific Reports 8, no. 1 (2018): 15539.

[555] Y. Sun, K. Oravecz-Wilson, S. Bridges, et al., “miR-142 Controls Metabolic Reprogramming That Regulates Dendritic Cell Activation,” The Journal of Clinical Investigation 129, no. 5 (2019): 2029–2042.

[556] M. Jayaraman, S. M. Ansell, B. L. Mui, et al., “Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing in Vivo,” Angewandte Chemie International Edition 51, no. 34 (2012): 8529–8533.

[557] Y. Zhang, H. Liu, W. Zhen, T. Jiang, and J. Cui, “Advancement of Drugs Conjugated with GalNAc in the Targeted Delivery to Hepatocytes Based on Asialoglycoprotein Receptor,” Carbohydrate Research 552 (2025): 109426.

[558] H. Kim, R. Zenhausern, K. Gentry, et al., “Lipid Nanoparticle-mediated mRNA Delivery to CD34+ Cells in rhesus Monkeys,” Nature Biotechnology 43, no. 11 (2025): 1813–1820.

[559] Y. Sun, Y. Chen, X. Ma, et al., “Mitochondria-targeted Hydroxyapatite Nanoparticles for Selective Growth Inhibition of Lung Cancer in Vitro and in Vivo,” ACS Applied Materials & Interfaces 8, no. 39 (2016): 25680–25690.

[560] A. Hendel, R. O. Bak, J. T. Clark, et al., “Chemically Modified Guide RNAs Enhance CRISPR-Cas Genome Editing in human Primary Cells,” Nature Biotechnology 33, no. 9 (2015): 985–989.

[561] L. Sakovina, I. Vokhtantsev, M. Vorobyeva, P. Vorobyev, and D. Novopashina, “Improving Stability and Specificity of CRISPR/Cas9 System by Selective Modification of Guide RNAs with 2′-fluoro and Locked Nucleic Acid Nucleotides,” International Journal of Molecular Sciences 23, no. 21 (2022): 13460.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.